

UNIVERSITY OF PENNSYLVANIA - PERELMAN SCHOOL OF MEDICINE
Curriculum Vitae

Date: 11/15/2022

Vincent Lo Re III, M.D., M.S.C.E.

Address: Center for Clinical Epidemiology and Biostatistics
836 Blockley Hall
423 Guardian Drive
Philadelphia, PA 19104 USA

If you are not a U.S. citizen or holder of a permanent visa, please indicate the type of visa you have:
none (U.S. citizen)

Education:

| | | |
|------|----------|---|
| 1992 | B.S. | Georgetown University (Chemistry) |
| 1997 | M.D. | University of Pennsylvania (Medicine) |
| 2005 | M.S.C.E. | University of Pennsylvania (Pharmacoepidemiology) |

Postgraduate Training and Fellowship Appointments:

| | |
|-----------|---|
| 1997-1998 | Intern in Medicine, Hospital of the University of Pennsylvania |
| 1998-2000 | Resident in Medicine, Hospital of the University of Pennsylvania |
| 2000-2001 | Chief Medical Resident, Hospital of the University of Pennsylvania |
| 2001-2003 | Fellow in Infectious Diseases, Hospital of the University of Pennsylvania |
| 2003-2007 | Research Fellow in Pharmacoepidemiology and Infectious Diseases Epidemiology, Division of Infectious Diseases and Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania |

Military Service:
[none]

Faculty Appointments:

| | |
|--------------|--|
| 2007-2008 | Instructor in Medicine and Epidemiology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania |
| 2008-2017 | Assistant Professor of Epidemiology in Biostatistics and Epidemiology, University of Pennsylvania School of Medicine (Secondary) |
| 2008-2017 | Assistant Professor of Medicine, University of Pennsylvania School of Medicine |
| 2017-present | Associate Professor of Epidemiology in Biostatistics and Epidemiology, University of Pennsylvania School of Medicine (Secondary) |

| | |
|--------------|--|
| 2017-present | Associate Professor of Medicine, University of Pennsylvania School of Medicine |
|--------------|--|

Hospital and/or Administrative Appointments:

| | |
|--------------|--|
| 2003-present | Attending Physician, Infectious Diseases Section, Medicine Service, Philadelphia Veterans Affairs Medical Center |
| 2004-present | Attending Physician, Infectious Diseases Division, Penn Presbyterian Medical Center |
| 2010-present | Attending Physician, Center for Viral Hepatitis, Perelman School of Medicine, University of Pennsylvania |
| 2015-present | Co-Director, NIGMS-funded T32 Pharmacoepidemiology Training Grant, Perelman School of Medicine |

Other Appointments:

| | |
|--------------|---|
| 2005-2008 | Faculty-Fellow, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania |
| 2008-present | Senior Scholar, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania |
| 2008-present | Member, Epidemiology and Biostatistics Graduate Group, Perelman School of Medicine, University of Pennsylvania |
| 2014-2017 | Co-Director HIV/Viral Hepatitis Coinfection Scientific Working Group, Penn Center for AIDS Research, Perelman School of Medicine, University of Pennsylvania |
| 2017-2021 | Co-Director, Clinical Core, Penn Center for AIDS Research, Perelman School of Medicine, University of Pennsylvania |
| 2018-present | Co-Director, Master of Science in Clinical Epidemiology Degree Program, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania |
| 2020-present | Member, Penn Center for Musculoskeletal Disorders |
| 2022-present | Director, Clinical Core, Penn Center for AIDS Research, Perelman School of Medicine, University of Pennsylvania |

Specialty Certification:

| | |
|------|---------------------|
| 2000 | Internal Medicine |
| 2003 | Infectious Diseases |
| 2005 | Epidemiology |

Licensure:

| | |
|--------------|----------------------------|
| 2000-present | Pennsylvania (MD-070718-L) |
|--------------|----------------------------|

Awards, Honors and Membership in Honorary Societies:

| | |
|------|--|
| 1992 | Chemistry Achievement Award, Georgetown University |
| 1992 | Phi Beta Kappa, Georgetown University |

| | |
|------|---|
| 1993 | Penn Geriatrics Scholarship, Edinburgh University, Edinburgh, Scotland |
| 1999 | Maurice F. Attie Junior Medical Resident Teaching Award, Perelman School of Medicine, University of Pennsylvania |
| 1999 | Pfizer Resident Award for Outstanding Performance in Infectious Diseases, Perelman School of Medicine, University of Pennsylvania |
| 2000 | Maurice F. Attie Senior Medical Resident Teaching Award, Perelman School of Medicine, University of Pennsylvania |
| 2001 | Francis H. Sterling Award for Educational Excellence, Philadelphia VA Medical Center and Perelman School of Medicine, University of Pennsylvania |
| 2001 | "Penn Pearls" Medical Student Teaching Award, Perelman School of Medicine, University of Pennsylvania |
| 2002 | Robert Austrian Outstanding Infectious Diseases Research Fellow Award, Perelman School of Medicine, University of Pennsylvania |
| 2005 | Young Investigator Award, 13th Conference on Retroviruses and Opportunistic Infections |
| 2005 | George McCracken Infectious Disease Fellow Travel Grant, 45th Interscience Conference on Antimicrobial Agents and Chemotherapy |
| 2006 | George McCracken Infectious Disease Fellow Travel Grant, 46th Interscience Conference on Antimicrobial Agents and Chemotherapy |
| 2006 | Young Investigator Award, 14th Conference on Retroviruses and Opportunistic Infections |
| 2007 | Top 30% Reviewer, Annals of Internal Medicine |
| 2008 | Top 5% Reviewer, Clinical Infectious Diseases |
| 2008 | Top 10% Reviewer, Annals of Internal Medicine |
| 2009 | Top 10% Reviewer, Annals of Internal Medicine |
| 2010 | Clinical Infectious Diseases Award for Outstanding Reviews |
| 2010 | Sandy Norman Epidemiology Teaching Award, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania |
| 2011 | Penn Department of Medicine Robert Austrian Award in Health Evaluation Research, Perelman School of Medicine, University of Pennsylvania |
| 2011 | Poster of Distinction Award, Digestive Disease Week |
| 2013 | Fellow, International Society for Pharmacoepidemiology |
| 2013 | Leonard Berwick Memorial Teaching Award, Penn Medicine Award of Excellence, Perelman School of Medicine, University of Pennsylvania |
| 2014 | Top 10% Reviewer, Annals of Internal Medicine |
| 2014 | Excellence in Teaching Epidemiology Award, Center for Clinical Epidemiology and Biostatistics, Perelman School of |

| | |
|------|---|
| | Medicine, University of Pennsylvania |
| 2016 | 2016 HIV Medicine Association Research Award, Infectious Diseases Society of America |
| 2020 | Clinical Practices of the University of Pennsylvania Sustainable Award, "A Sustained and Enhanced Initiative for HIV Treatment and HIV/HCV Coinfection Eradication Program in the MacGregor Infectious Diseases Practice" |
| 2021 | Harvey M. Friedman Infectious Diseases Faculty Mentoring Award, Perelman School of Medicine, University of Pennsylvania |
| 2021 | Harold I. Feldman Distinguished Faculty Award, Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania |
| 2022 | COVID-19 Pharmacoepidemiology Research Award, International Society for Pharmacoepidemiology |

Memberships in Professional and Scientific Societies and Other Professional Activities:

International:

| | |
|--------------|--|
| 2005-present | International AIDS Society (Member) |
| 2006-present | International Society for Pharmacoepidemiology (Member, 2006-Present; Membership Committee Member, 2009-Present; Membership Committee Vice-Chair, 2011-2013; Membership Committee Chair, 2013-2014; Education Committee Member, 2010-Present; Academic Council Member, 2013-Present; Fellow, 2013-Present; Strategic Planning Committee Member, 2015-2018; Strategic Planning Committee Chair, 2020-2021; Board of Directors, 2015-2018 and 2020-2023; Re-Branding Committee, 2018-2019; President-Elect, 2020-2021; President, 2021-2022; Fellowship and Awards Committee Chair, 2022-2023; Nominating Committee Chair, 2022-2023; Management Oversight Committee Chair, 2022-2023) |
| 2011 | Health Research Board of Ireland: Clinical and Applied Biomedical Research, Infectious Diseases Study Section, Dublin, Ireland (Member) |
| 2014-present | International Conference on Pharmacoepidemiology & Therapeutic Risk Management Scientific Program Committee (Member, 2014-2022; Newcomer Track Director, 2014-2017; Scientific Program Chair, 2019) |

National:

| | |
|--------------|--|
| 2001-present | Infectious Diseases Society of America (IDSA) (Member, 2001-Present; Fellow, 2015-Present; Research Committee Member, 2015-2018) |
| 2004-present | American Association for the Study of Liver Diseases (Member) |
| 2005-present | American College of Epidemiology (Member) |
| 2005-present | HIV Medicine Association (Member) |

| | |
|--------------|---|
| 2005-present | Society for Epidemiologic Research (Member) |
| 2007-present | Veterans Aging Cohort Study (VACS) (Member, 2007-Present; Liver Core Member, 2007-Present; Co-Chair Liver Core, 2009-Present; Executive Committee Member, 2010-Present; Publications Committee Member, 2017-2022) |
| 2010-present | North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) (Member, Liver Disease Working Group, 2010-Present; HIV/HBV Coinfection Lead, 2014-Present) |
| 2011-2013 | FDA Mini-Sentinel Severe Liver Injury Validation Workgroup (Workgroup Leader, 2011-2013) |
| 2013 | National Institutes of Health (Study Section Member, Special Emphasis Panel/Scientific Review Group ZAI1-SM-M-C1 Study Section) |
| 2013-2015 | US Food and Drug Administration (FDA) Antiviral Drugs Advisory Committee (Member) |
| 2014-present | American Conference for the Treatment of HIV (Program Committee Member, 2014-Present; HIV/Viral Hepatitis Program Co-Chair, 2014-Present; Steering Committee, 2016-Present; Conference Chair, 2021-2023) |
| 2015-2017 | National Academies of Sciences, Engineering, and Medicine Committee for a National Strategy for the Elimination of Hepatitis B and C (Member) |
| 2015-2018 | US Food and Drug Administration (FDA) Antimicrobial Drugs Advisory Committee (Member) |
| 2015 | US Food and Drug Administration (FDA) Pharmacy Compounding Advisory Committee (Ad Hoc Member, 2015) |
| 2015 | VA Healthcare Network Competitive Pilot Project Fund (Study Section Member) |
| 2016 | AIDS Clinical Trials Group (ACTG) Hepatitis External Advisory Committee (Member) |
| 2017-present | American Association for the Study of Liver Diseases (AASLD)/Infectious Diseases Society of America (IDSA) Hepatitis C Guidance Panel (Member, 2017-present; IDSA Co-Chair, 2022-2023) |
| 2017-2020 | FDA Sentinel Serious Infection Validation Workgroup (Workgroup Leader, 2017-2020) |
| 2017 | National Institutes of Health (Study Section Member, Special Emphasis |

Panel/Scientific Review Group ZRG1 AARR-E (83) S, "Multidisciplinary Studies of HIV and Viral Hepatitis Co-Infection" Study Section)

| | |
|--------------|--|
| 2017 | US Food and Drug Administration (FDA) Drug Safety and Risk Management Advisory Committee (Ad Hoc Member, 2017) |
| 2018-2020 | AIDS Clinical Trials Group Hepatitis Transformative Science Group (Member) |
| 2019 | National Institutes of Health (Study Section Member, AIDS Research Review Committee) |
| 2020-present | FDA Sentinel Assessment of the Natural History of Coagulopathy in COVID-19 Workgroup (Workgroup Leader, 2020-present) |
| 2020-2022 | National Psoriasis Foundation COVID-19 Task Force (Member) |
| 2021-2024 | US Food and Drug Administration (FDA) Drug Safety and Risk Management Advisory Committee (Member, 2021-2024; Chair, 2022-2024) |
| 2022 | National Institutes of Health (Study Section Member, HIV Comorbidities and Clinical Studies Study Section) |

Editorial Positions:

| | |
|--------------|---|
| 2002-2004 | Editor, Infectious Diseases Hot Topics, Philadelphia: Hanley & Belfus, 2004 |
| 2002-2004 | Editorial Advisory Board Member, JAMA, "On Call-Issues in Graduate Medical Education" Section |
| 2005-present | Peer Reviewer, Pharmacoepidemiology and Drug Safety |
| 2005-present | Peer Reviewer, Annals of Internal Medicine |
| 2005-present | Peer Reviewer, Clinical Infectious Diseases |
| 2007-present | Peer Reviewer, Gastroenterology |
| 2007-present | Peer Reviewer, Clinical Microbiology Reviews |
| 2007-present | Peer Reviewer, International Journal of Infectious Diseases |
| 2008-present | Peer Reviewer, HIV Clinical Trials |
| 2009-present | Peer Reviewer, JAIDS |
| 2009-present | Peer Reviewer, Liver International |
| 2009-2017 | Associate Editor, Pharmacoepidemiology and Drug Safety |
| 2009-present | Peer Reviewer, BMC Infectious Diseases |
| 2010-present | Peer Reviewer, BMC Gastroenterology |
| 2010-2013 | Associate Editor, BMC Infectious Diseases |
| 2010-present | Peer Reviewer, HIV Medicine |
| 2010-present | Peer Reviewer, European Journal of Gastroenterology and Hepatology |
| 2011-present | Peer Reviewer, Journal of Medical Virology |
| 2011-present | Peer Reviewer, Hepatology |

| | |
|--------------|--|
| 2011-present | Peer Reviewer, Journal of Hepatology |
| 2011-present | Peer Reviewer, British Journal of Clinical Pharmacology |
| 2012-present | Peer Reviewer, AIDS and Behavior |
| 2013-present | Peer Reviewer, Antiviral Therapy |
| 2013-present | Peer Reviewer, AIDS |
| 2014-present | Peer Reviewer, New England Journal of Medicine |
| 2014-present | Peer Reviewer, Journal of Antimicrobial Chemotherapy |
| 2015-present | Peer Reviewer, The Lancet |
| 2016-present | Peer Reviewer, Drug Safety |
| 2017-present | Peer Reviewer, Proceedings of the National Academy of Sciences |
| 2017-present | Peer Reviewer, JAMA Internal Medicine |
| 2018-present | Regional Editor for the Americas, Pharmacoepidemiology and Drug Safety |
| 2022-present | Peer Reviewer, JAMA |

Academic and Institutional Committees:

| | |
|--------------|--|
| 2000-2001 | Chair, House Staff Committee, Hospital of the University of Pennsylvania |
| 2000-2001 | Member, Graduate Medical Education Committee, Hospital of the University of Pennsylvania |
| 2006-2013 | Member, Intern Selection Committee, Hospital of the University of Pennsylvania |
| 2007-2009 | Member, Fellowship Selection Committee, Division of Infectious Diseases, Department of Medicine Perelman School of Medicine, University of Pennsylvania |
| 2008-2020 | Member, Service Center Committee, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania |
| 2009-2020 | Member, Steering Committee, Center for Viral Hepatitis, Perelman School of Medicine, University of Pennsylvania |
| 2011-2020 | Chair, Service Center Committee, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania |
| 2011-2017 | Member, Special Programs in Education Committee, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania |
| 2012-present | Member, Curriculum Committee, Master of Science in Clinical Epidemiology Degree Program, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania |
| 2012-present | Member, Admissions Committee, Master of Science in Clinical Epidemiology Degree Program, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania |
| 2013 | Member, Medical Student Research Paper Prize Committee, Perelman School of Medicine, University of Pennsylvania |

| | |
|--------------|--|
| 2013-2016 | Chair, Data Safety Monitoring Board, "A Placebo controlled trial of varenicline for smoking among those with HIV/AIDS" (R01 DA033681; PI, Robert A. Schnoll, PhD), Perelman School of Medicine, University of Pennsylvania |
| 2014-present | Member, Infectious Diseases Research Group, Division of Infectious Diseases, Department of Medicine, Perelman School of Medicine, University of Pennsylvania |
| 2014-present | Member, Gastroenterology and Hepatology Clinical Research Program, Division of Gastroenterology, Department of Medicine, Perelman School of Medicine, Department of Medicine, University of Pennsylvania |
| 2015 | Member, Search Committee, Academic Clinician and Epidemiologist, Good Shepherd Penn Partners, Perelman School of Medicine, University of Pennsylvania |
| 2017-present | Vice Chair, Reputation/Visibility Committee, Penn Division of Infectious Diseases, Department of Medicine, Perelman School of Medicine, University of Pennsylvania |
| 2017-present | Member, Research Advisory Committee, Department of Medicine, Perelman School of Medicine, University of Pennsylvania |
| 2018-2019 | Chair, Search Committee, Division of Gastroenterology Tenure Track Physician-Scientist, Department of Medicine, Perelman School of Medicine, University of Pennsylvania |
| 2018-present | Member, Committee on Appointments and Promotions, Department of Medicine, Perelman School of Medicine, University of Pennsylvania |
| 2020-present | Member, Measey Scholars Program Review Committee, Department of Medicine, Perelman School of Medicine, University of Pennsylvania |
| 2020-present | Member, Professionalism Committee, Department of Medicine, Perelman School of Medicine, University of Pennsylvania |
| 2020-present | Executive Committee Member, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania |
| 2020-present | Co-Chair, Research Support Working Group, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania |
| 2022 | Member, Search Committee, Department of Biostatistics, Epidemiology, and Informatics Vice-Chair of Faculty Professional Development |

Major Academic and Clinical Teaching Responsibilities:

| | |
|-----------|--|
| 2005-2013 | Lecturer, "Overview of Viral Hepatitis," Frontiers in Medicine Course for Fourth-Year Penn Medical Students |
| 2006-2013 | Course Co-Director, Clinical Investigator Toolbox elective rotation for 2nd and 3rd year Medical Residents, Hospital of the University of Pennsylvania |

| | |
|--------------|--|
| 2006-2019 | Lecturer, "Challenges in Conducting Epidemiologic Studies of HIV/Viral Hepatitis Coinfection," Epidemiological Methods in Infectious Diseases EPID 656 |
| 2007-present | Attending Physician, Penn Center for Viral Hepatitis, Penn Presbyterian Medical Center, 1 session/week |
| 2007-present | Attending Physician, Infectious Diseases Consultation Service, Penn Presbyterian Medical Center, 4 weeks/year |
| 2008-2009 | Faculty Mentor and Research Advisor, Jennifer Lin, MD, Penn Medical Resident |
| 2008-2010 | Faculty Mentor and Research Advisor, Michelle DallaPiazza, MD, Penn Medical Resident |
| 2008-2010 | Faculty Mentor and Research Advisor, Omowunmi Aibana, MD, Penn Medical Student Penn Scholarly Pursuit Research; Brigham and Women's Hospital Medical Resident |
| 2008-2009 | Junior Faculty Mentor and Research Advisor, Adeel A. Butt, MD, MSc, Assistant Professor of Medicine Infectious Diseases, University of Pittsburgh Medical Center |
| 2008-2013 | Infectious Diseases Fellows Educational Lecture Series, "Management of Chronic HCV Infection in HIV" |
| 2008-2015 | Faculty Mentor and Research Advisor, Alexis Ogdie-Beatty, MD, Penn Medical Resident; Penn Rheumatology Fellow; Assistant Professor of Medicine Rheumatology and Epidemiology, Perelman School of Medicine |
| 2008-2011 | Faculty Mentor and Research Advisor, Carrie L. Kovarik, MD, Assistant Professor of Dermatology, Perelman School of Medicine |
| 2009-2018 | Course Director and Instructor, Biostatistics for Epidemiologic Methods Laboratory EPID 526-527, 24 weeks, 1.5 hour lectures per week |
| 2009-2012 | Faculty Advisor and Master of Science in Clinical Epidemiology Thesis Committee Chair, Jeffrey S. Hafkin, MD, MSCE, Infectious Diseases Fellow, 1 hour per week for 36 months, 144 contact hours, resulted in abstract at CROI and Journal publication |
| 2009-2010 | Faculty Mentor and Research Advisor, Jessica A. Palakshappa, MD, MS, 4th year Penn Medical Student, 3 hours per week for 10 months, 120 contact hours resulted in Penn FOCUS Grant; 2 abstracts presented at 2011 CROI conference; Co-Author Journal publication |
| 2009-2010 | Faculty Mentor and Research Advisor, Valerianna K. Amorosa, MD Assistant Professor of Medicine Infectious Diseases, Perelman School of Medicine |
| 2009-2012 | Faculty Mentor and Research Advisor, Zachariah Dorey-Stein, Temple University Medical Student |
| 2010-2013 | Lecturer, "Effect of HCV on Bone Density and Fractures," Frontiers in Medicine Course for Fourth-Year Penn Medical Students |
| 2010-2015 | Faculty Advisor and Master of Science in Clinical Epidemiology Thesis Committee Chair, Hillary Hernandez-Trujillo, MD, MSCE; |

| | |
|--------------|--|
| | CHOP Immunology Fellow |
| 2010-2011 | Faculty Mentor and Research Advisor, Ingi Lee, MD, MSCE, Assistant Professor of Medicine Infectious Diseases, Perelman School of Medicine, resulted in 2010 Penn Center for Education and Research on Therapeutics Pilot Grant, Oral Abstract Presentation in 2011 American Transplant Congress, and Journal Publication |
| 2010-2020 | Faculty Mentor and Research Advisor, Kimberly A. Forde, MD, PhD, MHS, Penn Gastroenterology Fellow; Assistant Professor of Medicine Gastroenterology and Epidemiology |
| 2010 | Presenter, "Complications of HIV/HCV Coinfection: Effect of HCV on Bone Density and Fractures," Penn Center for Viral Hepatitis Research Symposium |
| 2010-2011 | Faculty Mentor and Research Advisor, Vijay Garla, PhD, Yale University Bioinformatics PhD Student |
| 2011-present | Lecturer, "Challenges in Conducting Cohort Studies to Examine the Epidemiology of Hepatitis C Virus Infection," GI Epidemiology (EPID 658) |
| 2011-2015 | Faculty Mentor and Research Advisor, David S. Goldberg, MD, MSCE, Penn Gastroenterology Fellow; Assistant Professor of Medicine Gastroenterology and Epidemiology |
| 2011-2015 | Co-Investigator on F31 Application, Lesley S. Park, PhD, Yale University PhD in Epidemiology Student |
| 2012-2016 | Faculty Advisor and Master of Science in Clinical Epidemiology Thesis Committee Chair, Dana D. Byrne, MD, MSCE; Penn Infectious Diseases Fellow |
| 2012 | Presenter, "Hepatic Decompensation in ART-Treated HIV/HCV-Coinfected Compared to HCV-Monoinfected Patients," Penn Center for Viral Hepatitis Research Symposium |
| 2012-2014 | Faculty Mentor and Research Advisor, Joseph K. Lim, MD, Assistant Professor of Medicine Gastroenterology, Yale School of Medicine |
| 2012-2016 | Master of Science in Clinical Epidemiology Thesis Committee Member, Beth N. Floyd, MD, MSCE; Penn Gastroenterology Fellow |
| 2013-2016 | Faculty Advisor and Master of Science in Clinical Epidemiology Thesis Committee Chair, Charitha Gowda, MD, MPH, MSCE; Penn Infectious Diseases Fellow; Awarded F32 from NIAID (2015); Awarded CROI Young Investigator Award and Penn Infectious Diseases Division Robert Austrian Research Award, both in 2016, in recognition of Master's thesis research accomplishments. Thesis featured in special topical collection on HIV and Hepatitis C Coinfection collated for the 9th International AIDS Society Conference on HIV Science 2017. |
| 2013-2014 | Faculty Mentor and Research Advisor, Baligh Yehia, MD, MPP, MSHP, Assistant Professor of Medicine Infectious Diseases, Perelman School of Medicine |
| 2013 | Viral Hepatitis Grand Rounds, "Bone Disease with Hepatitis C Virus |

| | |
|--------------|---|
| | Infection and HIV/Hepatitis C Coinfection" |
| 2013 | Infectious Diseases Grand Rounds, "Hepatic Decompensation in ART-Treated HIV/HCV-Coinfected Compared to HCV-Monoinfected Patients" |
| 2013-present | Lecture to Penn Medical Residents, "Management of Chronic HCV in HIV" |
| 2014-2017 | Faculty Advisor and Master of Science in Clinical Epidemiology Thesis Committee Chair, Tatyana Kushner, MD, MSCE; Penn Gastroenterology Fellow; Awarded 2017 NIH Loan Repayment Program, Frank Brooks Research Award by Penn Gastroenterology Division, and 48th Annual Komarov Prize for GI Research in recognition of Master's thesis research accomplishments. 2018 AASLD Clinical, Translational and Outcomes Research Award in Liver Diseases for postdoctoral research. |
| 2014 | Viral Hepatitis Grand Rounds, "HIV/Hepatitis C Virus Coinfection: Interactive Cases" |
| 2014 | Presenter, "Structural Bone Deficits in HIV/HCV, HCV-Monoinfected, and HIV-Monoinfected Women," Penn Center for AIDS Annual Research Retreat |
| 2014-2016 | Faculty Mentor and Research Advisor, M. Elle Saine, MA, Penn Pre-Health Post-Baccalaureate Program Student, Penn Medical Student |
| 2014-2017 | Faculty Mentor and Doctoral Thesis Committee Member, Bret Zeldow, Penn PhD in Biostatistics Student, weekly meetings |
| 2014 | Infectious Diseases Grand Rounds, "Predicting Risk of End-Stage Liver Disease in HIV/HCV Patients: Can We Forecast Liver Complications?" |
| 2014 | Infectious Diseases Grand Rounds, "Structural Bone Deficits in HIV/HCV-Coinfected, HCV-Monoinfected, and HIV-Monoinfected Women" |
| 2015-present | Lecturer, "Use of Automated Databases for Comparative Effectiveness Research," Methods in Patient-Centered Outcomes and Effectiveness Research EPID 624 |
| 2015 | Viral Hepatitis Grand Rounds, "Epidemiology and Treatment of HIV/HCV Coinfection: 2015 Update" |
| 2015 | Infectious Diseases Grand Rounds, "Drug-Induced Acute Liver Failure" |
| 2016 | Center for Clinical Epidemiology and Biostatistics Weekly Seminar, "Pharmacoepidemiology of Drug-Induced Acute Liver Failure" |
| 2016 | Division of General Internal Medicine Grand Rounds, "Epidemiology of HIV/Viral Hepatitis Coinfection" |
| 2016-2018 | Master of Science in Clinical Epidemiology Thesis Committee Member, Dagan E. Coppock, MD; Penn Infectious Diseases Fellow |
| 2016-2018 | Course Director, Biostatistics for Epidemiologic Methods Lectures EPID 526-527, 24 weeks, 3.0 hour lectures per week |
| 2016-2017 | Faculty Mentor and Research Advisor, Mona Gizaw, Penn |

| | |
|--------------|--|
| 2016-present | Undergraduate Student, Penn Access Summer Scholars Program Faculty Mentor and Research Advisor, Jessie Torgersen, MD, MSCE; Penn Infectious Diseases Fellow and Instructor; Highlighted Poster Presentation at 16th International Conference in Malignancies in HIV/AIDS (2017); CROI Young Investigator Award (2017); Oral abstract presentation at CROI 2019. |
| 2016-2017 | Faculty Mentor and Research Advisor, Kirsten Lum, PhD, Penn Department of Biostatistics, Epidemiology, and Informatics Postdoctoral Research Fellow |
| 2017 | Division of Gastroenterology Interdisciplinary Grand Rounds, "Hepatitis B Reactivation" |
| 2017-2019 | Faculty Advisor and Master of Science in Clinical Epidemiology Thesis Committee Chair, Joanna M. Rhodes, MD, MSCE; Penn Hematology and Oncology Fellow. Awarded 2019 American Society for Clinical Oncology Conquer Cancer Foundation Young Investigator Award |
| 2017-2020 | Doctoral Thesis Committee Member, Wei (Vivian) Wang, University of Florida PhD in Pharmacoepidemiology Student |
| 2017-present | Faculty Mentor and Doctoral Thesis Committee Member, M. Elle Saine, PhD, Penn MD/PhD in Epidemiology Student, weekly meetings. Awarded Penn Leonard Davis Institute 2018 Pilot Grant; Awarded the Clinical Epidemiology Research Paper Prize and Herbert and Faye Moskowitz Prize in Epidemiology for her PhD dissertation by the Perelman School of Medicine of the University of Pennsylvania. |
| 2018-present | Faculty Advisor and Master of Science in Clinical Epidemiology Thesis Committee Chair, Nicole Ferrante, MD, Penn Gastroenterology Fellow, Awarded 2021 Penn Developmental Microgrant |
| 2018-present | Co-Director, Master of Science in Clinical Epidemiology Degree Program, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania |
| 2019-present | Faculty Advisor and Master of Science in Clinical Epidemiology Thesis Committee Chair, Erica Weinstein, MD; Penn Infectious Diseases Fellow |
| 2019 | Lecturer, "Hepatitis C Infection: Diagnosis and Treatment 2019" Penn Infectious Diseases Update 2019 for Primary Care CME conference, Philadelphia, PA |
| 2019-present | Faculty Mentor and Research Advisor, Jessica Kim, Drexel University Medical Student |
| 2019-present | Course Director and Instructor, Clinical Database Research Methodology EPID 5460, 7 weeks, 3.0 hour lectures per week |
| 2019-present | Faculty Mentor and Research Advisor, Alyssa Mezocho, Penn Medical Resident and Infectious Diseases Fellow |
| 2020 | Pennsylvania Hospital Department of Medicine Grand Rounds, "Management of Hepatitis C Virus Infection: Approach to Diagnosis |

| | |
|--------------|---|
| | and Initial Therapy in 2020" |
| 2021-2022 | Lecturer, "Opportunities and Challenges With Using Real-World Data for the Conduct of COVID-19 Pharmacoepidemiology Studies," EPID 0705 Intermediate Pharmacoepidemiology, Rutgers University |
| 2021-present | Faculty Advisor and Master of Science in Clinical Epidemiology Thesis Committee Chair, Nicole Ferrante, MD; Penn Gastroenterology Fellow |
| 2021-present | Doctoral Thesis Committee Member, Basile Njei, MD, Yale University PhD in Epidemiology Student |
| 2022 | Penn Department of Biostatistics, Epidemiology, and Informatics Distinguished Faculty Speaker, "Risk of Arterial and Venous Thrombotic Events in Patients with COVID-19 vs. Influenza: A Cohort Study in the US FDA's Sentinel System" 2022 Penn Department of Biostatistics, Epidemiology, and Informatics & Center for Clinical Epidemiology and Biostatistics Research Day |

Lectures by Invitation (Last 5 years):

| | |
|-----------|---|
| Mar, 2017 | "Drug-Induced Acute Liver Failure: A Concern for Clinicians?" Department of Medicine Seminar, Princess Marina Hospital, Gaborone, Botswana |
| Mar, 2017 | "Epidemiology and Management of Chronic Hepatitis B in HIV" Botswana HIV Clinicians Society Meeting, University of Botswana, Gaborone, Botswana |
| Mar, 2017 | "Use of Automated Databases for Clinical Epidemiologic Research" University of Botswana Research Seminar, Gaborone, Botswana |
| Apr, 2017 | "A National Strategy for the Elimination of Hepatitis B and C in the US: Eliminating Hepatitis C Morbidity and Mortality" CDC Foundation Summit for the Elimination of Hepatitis B and Hepatitis C as Public Health Threats in the United States, Atlanta, GA |
| Apr, 2017 | "HIV/Hepatitis C Virus Coinfection Management" American Conference for the Treatment of HIV 2017, Dallas, TX |
| Aug, 2017 | "Establishing Productive Mentor-Mentee Relationships in Pharmacoepidemiology" 33rd International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Montreal, Canada |
| Aug, 2017 | "How to Manage a Pharmacoepidemiology-Based Research Team" 33rd International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Montreal Canada |
| Aug, 2017 | "How to Manage a Pharmacoepidemiology-Based Research Team" 33rd International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Montreal, Canada |
| Oct, 2017 | "Use of Pharmacoepidemiology Databases to Answer Clinically Relevant Questions" 10th Asian Conference on Pharmacoepidemiology, University of Queensland, Brisbane, Australia |

| | |
|-----------|---|
| Oct, 2017 | "Evaluation of Clinical Outcomes in Automated Pharmacoepidemiology Databases" 10th Asian Conference on Pharmacoepidemiology, University of Queensland, Brisbane, Australia |
| Oct, 2017 | "A National Strategy for the Elimination of Hepatitis B and C in the US" Philadelphia Department of Public Health, Philadelphia, PA |
| Oct, 2017 | "Use of Automated Databases for Pharmacoepidemiology Research" 10th Asian Conference on Pharmacoepidemiology, University of Queensland, Brisbane, Australia |
| Nov, 2017 | "Use of Automated Databases for Pharmacoepidemiologic Research" FDA Introduction to Pharmacoepidemiologic Research Methods, FDA White Oak Campus, Silver Spring, MD |
| Jun, 2018 | "Use of Automated Databases for Pharmacoepidemiology Research" 4th Medicines Utilization Research in Africa (MURIA) Conference, University of Namibia, Windhoek, Namibia |
| Jun, 2018 | "Protocol Development for Pharmacoepidemiology Research" 4th Medicines Utilization Research in Africa (MURIA) Conference, University of Namibia, Windhoek, Namibia |
| Jun, 2018 | "Confounding and Bias in Pharmacoepidemiology Research" 4th Medicines Utilization Research in Africa (MURIA) Conference, University of Namibia, Windhoek, Namibia |
| Jun, 2018 | "Evaluating Drug Exposure and Outcomes in Pharmacoepidemiology Databases" 4th Medicines Utilization Research in Africa (MURIA) Conference, University of Namibia, Windhoek, Namibia |
| Jun, 2018 | "Overview of Pharmacoepidemiology Research Methods" 4th Medicines Utilization Research in Africa (MURIA) Conference, University of Namibia, Windhoek, Namibia |
| Jun, 2018 | "Statistical Test Selection in Epidemiologic Research" 4th Medicines Utilization Research in Africa (MURIA) Conference, University of Namibia, Windhoek, Namibia |
| Jun, 2018 | "Case-Control Studies" 4th Medicines Utilization Research in Africa (MURIA) Conference, University of Namibia, Windhoek, Namibia |
| Jun, 2018 | "Cohort Studies" 4th Medicines Utilization Research in Africa (MURIA) Conference, University of Namibia, Windhoek, Namibia |
| Jun, 2018 | "Determinants of Hepatocellular Carcinoma Among HIV-Infected Patients" Works in Progress Conference, VA Connecticut Healthcare System/Yale School of Medicine, West Haven, CT |
| Aug, 2018 | "Establishing Productive Mentor-Mentee Relationships in Pharmacoepidemiology" 34th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Prague, Czech Republic |
| Aug, 2018 | "How to Manage a Pharmacoepidemiology-Based Research Team" 34th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Prague, Czech Republic |
| Aug, 2018 | "Enhancing Creativity and Productivity in Pharmacoepidemiology" |

| | |
|-----------|--|
| | 34th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Prague, Czech Republic |
| Sep, 2018 | "Epidemiology of End-Stage Liver Disease and Hepatocellular Carcinoma in HIV-Infected Persons" HIV and Liver Disease Biennial Conference 2018, Moran, WY |
| Oct, 2018 | "Use of Automated Databases for Pharmacoepidemiology Research" 11th Asian Conference on Pharmacoepidemiology, Xi'an, China |
| Oct, 2018 | "Evaluation of Clinical Outcomes in Automated Pharmacoepidemiology Databases" 11th Asian Conference on Pharmacoepidemiology, Xi'an, China |
| Oct, 2018 | "Use of Pharmacoepidemiology Databases to Answer Clinically Relevant Questions" 11th Asian Conference on Pharmacoepidemiology, Xi'an, China |
| Aug, 2019 | "How to Manage a Pharmacoepidemiology-Based Research Team" 35th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Philadelphia, PA |
| Sep, 2019 | "How Do HIV, Risk Behaviors, and ART Influence Aging Syndromes?" NIH Workshop on HIV-Associated Comorbidities, Coinfections, and Complications, Bethesda, MD |
| Oct, 2019 | "Use of Pharmacoepidemiology Databases to Answer Clinically Relevant Questions" 12th Asian Conference on Pharmacoepidemiology, Kyoto, Japan |
| Oct, 2019 | "Use of Healthcare Databases for Pharmacoepidemiology Research" 12th Asian Conference on Pharmacoepidemiology, Kyoto, Japan |
| Oct, 2019 | "Evaluation of Clinical Outcomes in Pharmacoepidemiology Databases" 12th Asian Conference on Pharmacoepidemiology, Kyoto, Japan |
| Oct, 2019 | "Validating Health Outcomes in Electronic Healthcare Databases: Methodology and Approaches in US Data Sources" 12th Asian Conference on Pharmacoepidemiology, Kyoto, Japan |
| Nov, 2019 | "Use of Healthcare Databases for Pharmacoepidemiologic Research" FDA Introduction to Pharmacoepidemiologic Research Methods, FDA White Oak Campus, Silver Spring, MD |
| Feb, 2020 | "Categorizing Drugs for Hepatotoxicity Potential by Evaluating Rates of Acute Liver Injury After Initiation of Use" VA Connecticut Healthcare System/Yale School of Medicine, West Haven, CT |
| Jun, 2020 | "Risk of Arterial and Venous Thrombotic Events With COVID-19: A Sentinel System Investigation" Reagan-Udall Foundation for the US Food and Drug Administration, Webinar |
| Jul, 2020 | "Assessment of Arterial and Venous Thrombotic Events With COVID-19 in the Sentinel System - Methods for Evaluation" Reagan-Udall Foundation for the US Food and Drug Administration, Webinar |
| Aug, 2020 | "Evaluation of Arterial and Venous Thrombotic Events With COVID-19 in the Sentinel System - Focus on Clinical Endpoints" Reagan-Udall Foundation for the US Food and Drug Administration, |

| | |
|-----------|---|
| | Webinar |
| Sep, 2020 | "Building Effective Relationships with Pharmacoepidemiology Mentors, Project Team Members, and Organizations/Networks" 36th International Conference on Pharmacoepidemiology & Therapeutic Risk Management - All Access Virtual Meeting |
| Oct, 2020 | "Studying the Natural History of COVID-19: Risk of Arterial and Venous Thrombotic Events in the Sentinel System" 12th Annual Sentinel Initiative Public Workshop Virtual Meeting |
| Oct, 2020 | "Natural History of Coagulopathy in COVID-19" International Coalition of Medicines Regulatory Authorities Webinar |
| Oct, 2020 | "Use of Healthcare Databases for Pharmacoepidemiologic Research" FDA Introduction to Pharmacoepidemiologic Research Methods, FDA Webinar |
| Mar, 2021 | "Assessment of the Natural History of Coagulopathy in COVID-19: Approaches to Analysis" Reagan-Udall Foundation for the US Food and Drug Administration, Webinar |
| Apr, 2021 | "Establishing a Productive Mentor-Mentee Relationship" International Society for Pharmacoepidemiology 2021 Virtual Mid-Year Meeting |
| Apr, 2021 | "Evaluation of Arterial and Venous Thrombotic Events in COVID-19" Reagan-Udall Foundation for the US Food and Drug Administration, Webinar |
| Aug, 2021 | "A Master Protocol to Identify COVID-19 and Relevant Data in the US FDA Sentinel System" 37th International Conference on Pharmacoepidemiology & Therapeutic Risk Management - All Access Virtual Meeting 2021 |
| Aug, 2021 | "Estimating Toxicities of Polypharmacy: Evaluating Rates of Severe Acute Liver Injury After Initiation of Drugs with Reports of Hepatotoxicity" 37th International Conference on Pharmacoepidemiology & Therapeutic Risk Management - All Access Virtual Meeting 2021 |
| Aug, 2021 | "Plenary Presentation: Role of Journal Editors in Communication of Pharmacoepidemiology Research to Public" 37th International Conference on Pharmacoepidemiology & Therapeutic Risk Management - All Access Virtual Meeting 2021 |
| Aug, 2021 | "Pharmacoepidemiologist's Toolbox for Professional Empowerment: How to Give and Receive Feedback Effectively" 37th International Conference on Pharmacoepidemiology & Therapeutic Risk Management - All Access Virtual Meeting 2021 |
| Sep, 2021 | "Liver Diseases Affecting People Living with HIV: What's Up, What's Down in 2021" HIV and Liver Disease Biennial Conference 2021, Teton Village, WY |
| Oct, 2021 | "Risk of Arterial and Venous Thrombotic Events With COVID-19" Reagan-Udall Foundation for the US Food and Drug Administration, Webinar |
| Oct, 2021 | Plenary Address: "Opportunities and Challenges in Using |

| | |
|-----------|---|
| | Real-World Data for the Conduct of COVID-19 Pharmacoepidemiology Studies" 13th Asian Conference on Pharmacoepidemiology, Seoul, Korea |
| Apr, 2022 | "Hepatic Steatosis in HIV: Validation of an Artificial Intelligence Tool for Assessment of Determinants and Outcomes of Steatosis" Veterans Aging Cohort Study Scientific Meeting, Washington, DC |
| Apr, 2022 | "Evaluating Rates of Severe Acute Liver Injury After Initiation of Drugs with Reports of Hepatotoxicity" Veterans Aging Cohort Study Scientific Meeting, Washington, DC |
| May, 2022 | "Opportunities and Challenges With Using Real-World Data for the Conduct of COVID-19 Pharmacoepidemiology Studies" Bordeaux Pharmacoepidemiology Festival, Bordeaux, France |
| Jun, 2022 | "Chronic Hepatitis C Infection: Management and Initial Therapy" 14th Prenatal Virtual Conference |
| Oct, 2022 | "Association of COVID-19 versus Influenza with Risk of Arterial and Venous Thrombotic Events Among Hospitalized Patients" Reagan-Udall Foundation for the US Food and Drug Administration, COVID-19 Webinar |

Organizing Roles in Scientific Meetings:

| | |
|-----------|--|
| Sep, 2010 | Organizer and Moderator, "Therapies for Viral Hepatitis," Scientific Symposium, 50th Interscience Conference on Antimicrobial Agents and Chemotherapy Boston, MA |
| Aug, 2013 | Organizer and Moderator "Challenges in Studying Drug-Induced Liver Injury in Pharmacoepidemiology Data Sources," Symposium 29th International Conference on Pharmacoepidemiology & Therapeutic Risk Management Montreal, Canada |
| Sep, 2014 | Moderator "Hepatitis and CMV: New and Noteworthy," Oral Abstract Session, 54th Interscience Conference on Antimicrobial Agents and Chemotherapy Washington, DC |
| Oct, 2014 | Moderator "World War V: Viruses and Vaccines," Oral Abstract Session, 30th International Conference on Pharmacoepidemiology & Therapeutic Risk Management Taipei, Taiwan |
| May, 2015 | Co-Organizer and Co-Moderator, "Viral Hepatitis" American Conference for the Treatment of HIV 2015 Dallas, TX |
| Aug, 2015 | Organizer and Moderator, "Establishing a Successful Early Stage Career in Pharmacoepidemiology" Pre-Conference Educational Course, 31st International Conference on Pharmacoepidemiology & Therapeutic Risk Management Boston, MA |
| Aug, 2015 | Moderator "Pharmacoepidemiology of Anti-Infectives and Steroids" |

| | |
|-----------|--|
| | Oral Abstract Session, 31st International Conference on Pharmacoepidemiology & Therapeutic Risk Management Boston, MA |
| May, 2016 | Co-Organizer and Co-Moderator, "HIV/Hepatitis C Virus Coinfection" American Conference for the Treatment of HIV 2016 Dallas, TX |
| Aug, 2016 | Organizer and Moderator, "Establishing a Successful Early Stage Career in Pharmacoepidemiology" Pre-Conference Educational Course, 32nd International Conference on Pharmacoepidemiology & Therapeutic Risk Management Dublin, Ireland |
| Apr, 2017 | Co-Organizer and Co-Moderator, "HIV/Viral Hepatitis Coinfection" American Conference for the Treatment of HIV 2017 Dallas, TX |
| Apr, 2017 | Scientific Organizing Committee Member, CDC Foundation Summit for the Elimination of Hepatitis B and Hepatitis C as Public Health Threats in the United States Atlanta, GA |
| Aug, 2017 | Organizer and Moderator, "Establishing a Successful Early Stage Career in Pharmacoepidemiology" Pre-Conference Educational Course, 33rd International Conference on Pharmacoepidemiology & Therapeutic Risk Management Montreal, Canada |
| Aug, 2017 | Moderator, "Epidemiology of Respiratory Viruses, HIV, and Chronic Lung Disease" Oral Abstract Session, 33rd International Conference on Pharmacoepidemiology & Therapeutic Risk Management Montreal, Canada |
| Oct, 2017 | Co-Organizer and Co-Moderator, "Use of Automated Databases for Pharmacoepidemiology Research" 10th Asian Conference on Pharmacoepidemiology University of Queensland, Brisbane, Australia |
| Apr, 2018 | Co-Organizer and Co-Moderator, "HIV/Viral Hepatitis Coinfection" American Conference for the Treatment of HIV 2018 Chicago, IL |
| Jun, 2018 | Organizer and Moderator, "Introduction to Pharmacoepidemiology" 4th Medicines Utilization Research in Africa (MURIA) Conference University of Namibia, Windhoek, Namibia |
| Aug, 2018 | Organizer and Moderator, "Establishing a Successful Early Stage Career in Pharmacoepidemiology" Pre-Conference Educational Course, 34th International Conference on Pharmacoepidemiology & Therapeutic Risk Management Prague, Czech Republic |
| Oct, 2018 | Co-Organizer and Co-Moderator, "Use of Automated Databases for Pharmacoepidemiology Research" 11th Asian Conference on Pharmacoepidemiology |

| | |
|-----------|--|
| | Xi'an, China |
| Apr, 2019 | Organizer and Moderator, "HIV and Liver Disease" American Conference for the Treatment of HIV 2019 Miami, FL |
| Aug, 2019 | Chair, Scientific Program Committee, 35th International Conference on Pharmacoepidemiology & Therapeutic Risk Management Philadelphia, PA |
| Aug, 2019 | Organizer and Moderator, "Establishing a Successful Early Stage Career in Pharmacoepidemiology" Pre-Conference Educational Course, 35th International Conference on Pharmacoepidemiology & Therapeutic Risk Management Philadelphia, PA |
| Aug, 2019 | Organizer and Moderator, "Keynote Session: The Role of Real-World Evidence in Regulatory Decision-Making" 35th International Conference on Pharmacoepidemiology & Therapeutic Risk Management Philadelphia, PA |
| Aug, 2019 | Organizer and Moderator, "Lightning Forum" 35th International Conference on Pharmacoepidemiology & Therapeutic Risk Management Philadelphia, PA |
| Nov, 2019 | Co-Organizer and Co-Moderator, "Use of Automated Databases for Pharmacoepidemiology Research" 12th Asian Conference on Pharmacoepidemiology Kyoto, Japan |
| Mar, 2020 | Co-Moderator, "Gone But Not Forgotten: HCV After Direct-Acting Antiviral Therapy" Oral Abstract Session, Conference on Retroviruses and Opportunistic Infections 2020 Boston, MA |
| Aug, 2020 | Organizer and Moderator, "HIV and Liver Disease" American Conference for the Treatment of HIV 2020 Virtual National Meeting |
| Sep, 2020 | Organizer and Moderator, "Real-World Evidence and COVID-19" 36th International Conference on Pharmacoepidemiology & Therapeutic Risk Management - All Access Virtual Meeting Virtual International Meeting |
| Apr, 2021 | Co-Moderator, Oral Abstract Session, "Pharmacoepidemiology in Contraception, Conception, and Beyond" International Society for Pharmacoepidemiology 2021 Virtual Mid-Year Meeting Virtual International Meeting |
| May, 2021 | Organizer and Moderator, "HIV and Liver Disease" American Conference for the Treatment of HIV 2021 Virtual National Meeting |
| Jun, 2021 | Panelist, "Risk Minimization Program Evaluation: How Can We Advance the Science?" Drug Information Association Global Annual Meeting 2021 |

| | |
|-----------|---|
| May, 2022 | Virtual International Meeting Co-Chair, Program Committee, American Conference for the Treatment of HIV 2022 Denver, CO |
| Aug, 2022 | Co-Moderator, Oral Abstract Session, "Pharmacoepidemiologic Methods and SARS-CoV-2" 38th International Conference for Pharmacoepidemiology & Therapeutic Risk Management Copenhagen, Denmark |
| May, 2023 | Co-Chair, Program Committee, American Conference for the Treatment of HIV 2023 Phoenix, AZ |

Bibliography:

Research Publications, peer reviewed (print or other media):

1. Lo Re V 3rd, Gasink L, Kostman, JR, Leonard D, Gross R: Natural history of patients with low-level HIV viremia on antiretroviral therapy. AIDS Patient Care STDs 18(8): 436-42, August 2004.
2. Ende A, Lo Re V 3rd, DiNubile MJ, Mounzer K: Erectile dysfunction in an urban HIV-positive population. AIDS Patient Care STDs 20(2): 75-8, February 2006.
3. Bisson GP, Frank I, Gross R, Lo Re V 3rd, Strom J, Wang X, Mogorosi M, Gaolathe T, Ndwapu N, Friedman H, Strom BL, Dickinson D: Out-of-pocket costs of HAART limit HIV treatment responses in Botswana's private sector. AIDS 20(9): 1333-6, June 2006.
4. Lo Re V 3rd, Schutte-Rodin S, Kostman JR: Obstructive sleep apnea among HIV patients. Int J STD AIDS 17(9): 614-20, September 2006.
5. Gross R, Yip B, Lo Re V 3rd, Wood E, Alexander C, Harrigan R, Bangsberg R, Montaner J, Hogg R: A simple, dynamic measure of antiretroviral therapy adherence predicts failure to maintain HIV-1 suppression. J Infect Dis 194(8): 1108-14, October 2006.
6. Lo Re V 3rd, Frank I, Gross R, Dockter J, Linnen JM, Giachetti C, Tebas P, Stern J, Synnestvedt M, Localio AR, Kostman JR, Strom BL: Prevalence, risk factors, and outcomes for occult hepatitis B virus infection among HIV-infected patients. J Acquir Immune Defic Syndr 44(3): 315-20, March 2007.
7. Lo Re V 3rd, Frank I, Gross R, Synnestvedt M, Localio AR, Kostman JR, Strom BL: Self-reported hepatitis B and C virus infections had low sensitivity among HIV-infected patients. J Clin Epidemiol 60(3): 294-9, March 2007.
8. Lo Re V 3rd, Kostman JR, Gross R, Reddy KR, Mounzer K, Zemel B, Rennert H, Stieritz D, Putt M, Frank I, Strom BL: Incidence and risk factors for weight loss during dual HIV/hepatitis C virus therapy. J Acquir Immune Defic Syndr 44(3):

344-50, March 2007.

9. McComsey GA, Lo Re V 3rd, O'Riordan M, Walker UA, Lebrecht D, Baron E, Mounzer K, Frank I: Effect of reducing the dose of stavudine on body composition, bone density, and markers of mitochondrial toxicity in HIV-infected subjects: a randomized, controlled study. Clin Infect Dis 46(8): 1290-6, April 2008.
10. Lo Re V 3rd, Wertheimer B, Localio AR, Kostman J, Dockter J, Linnen J, Giachetti C, Tebas P, Frank I, Strom BL, Gross R: Incidence of transaminitis among HIV-infected patients with occult hepatitis B. J Clin Virol 43(1): 32-6, September 2008.
11. Butt AA, Khan UA, Shaikh OS, McMahon D, Dorey-Stein Z, Tsevat J, Lo Re V 3rd: Rates of HCV treatment eligibility among HCV-monoinfected and HCV/HIV-coinfected patients in tertiary care referral centers. HIV Clin Trials 10(1): 25-32, January-February 2009.
12. Lo Re V 3rd, Amorosa VK, Localio R, O'Flynn R, Teal V, Dorey-Stein Z, Kostman JR, Gross R: Adherence to hepatitis C virus therapy and early virologic outcomes. Clin Infect Dis 48(2): 186-93, January 2009.
13. Butt AA, Tsevat J, Leonard AC, Shaikh OS, McMahon D, Khan UA, Dorey-Stein Z, Lo Re V 3rd: Effect of race and HIV co-infection upon treatment prescription for hepatitis C virus. Int J Infect Dis 13(4): 449-55, July 2009.
14. Lo Re V 3rd, Haynes K, Forde K, Localio AR, Schinnar R, Lewis JD: Validity of The Health Improvement Network (THIN) for epidemiologic studies of hepatitis C virus infection. Pharmacoepidemiol Drug Saf 18(9): 807-14, September 2009.
15. Lo Re V 3rd, Guaraldi G, Leonard MB, Lin J, Orlando G, Squillace N, Rochira V, Giovanni C, Kostman JR, Tebas P: Viral hepatitis coinfection is associated with reduced bone mineral density in HIV-infected women but not men. AIDS 23(16): 2191-8, October 2009.
16. Amorosa VK, Slim J, Mounzer K, Bruno C, Hoffman-Terry M, Dorey-Stein Z, Ferrara T, Kostman JR, Lo Re V 3rd: The influence of abacavir and other antiretroviral agents on virologic response to hepatitis C virus therapy among antiretroviral-treated HIV-infected patients. Antivir Ther 15(1): 91-9, February 2010.
17. DallaPiazza M, Amorosa VK, Localio AR, Kostman JR, Lo Re V 3rd: Prevalence and risk factors for significant liver fibrosis among HIV-monoinfected patients. BMC Infect Dis 10: 116, May 13 2010.
18. Szep Z, Guaraldi G, Shah SS, Lo Re V 3rd, Ratcliffe SJ, Orlando G, Carli F, Rossi R,

Rochira V, Tebas P: Vitamin D deficiency is associated with type 2 diabetes mellitus among HIV-infected patients. AIDS 25(4): 525-9, February 2011.

19. Garla V, Lo Re V 3rd, Dorey-Stein Z, Kidwai F, Scotch M, Womack J, Justice A, Brandt C: The Yale cTAKES Extensions for Document Classification: Architecture and application. J Am Med Inform Assoc 18(5): 614-20, May 2011.
20. Lo Re V 3rd, Lim JK, Goetz MB, Tate J, Bathulapalli H, Klein MB, Rimland D, Rodriguez-Barradas MC, Butt AA, Gibert CL, Brown ST, Kidwai F, Brandt C, Dorey-Stein Z, Reddy KR, Justice AC: Validity of diagnostic codes and liver-related laboratory abnormalities to identify hepatic decompensation events in the Veterans Aging Cohort Study. Pharmacoepidemiol Drug Saf 20(7): 689-99, July 2011.
21. Lo Re V 3rd, Teal V, Localio AR, Amorosa VK, Kaplan DE, Gross R: Relationship between adherence to hepatitis C virus therapy and virologic outcomes. Ann Intern Med 155(6): 353-60, September 2011.
22. Lee I, Localio AR, Brensinger CM, Blumberg EA, Lautenbach E, Gasink L, Amorosa VK, Lo Re V 3rd: Decreased post-transplant survival among heart transplant recipients with pre-transplant hepatitis C virus positivity. J Heart Lung Transplant 30(11): 1266-74, November 2011.
23. Park L, Tate J, Justice A, Lo Re V 3rd, Lim J, Bräu N, Brown S, Butt A, Gibert C, Goetz M, Rimland D, Rodriguez-Barradas M, Dubrow R: FIB-4 index predicts hepatocellular carcinoma risk in HIV-infected patients. Cancer Epidemiol Biomarkers Prev 20(12): 2512-7, December 2011.
24. Forde KA, Haynes K, Troxel A, Trooskin S, Osterman MT, Kimmel SE, Lewis JD, Lo Re V 3rd: Risk of myocardial infarction associated with hepatitis C virus infection: A population-based cohort study. J Viral Hepat 19(4): 271-7, April 2012.
25. Goldberg DS, Lewis JD, Halpern SD, Weiner M, Lo Re V 3rd: Validation of three coding algorithms to identify patients with end-stage liver disease in an administrative database. Pharmacoepidemiol Drug Saf 21(7): 765-9, July 2012.
26. Hernandez-Trujillo HS, Chapel H, Lo Re V 3rd, Notarangelo LD, Gathmann B, Grimbacher B, Boyle JM, Hernandez-Trujillo VP, Scalchunes C, Boyle ML, Orange JS: Comparison of American and European practices in the management of patients with primary immunodeficiencies. Clin Exp Immunol 169(1): 57-69, July 2012.
27. Lo Re V 3rd, Haynes K, Ming EE, Wood Ives J, Horne LN, Fortier K, Carbonari DM, Hennessy S, Cardillo S, Reese PP, Reddy KR, Margolis D, Apter A, Kimmel SE, Roy J, Freeman CP, Razzaghi H, Holick CN, Esposito DB, Van Staa TP,

Bhullar H, Strom BL: Safety of saxagliptin: Rationale for and design of a series of postmarketing observational studies. Pharmacoepidemiol Drug Saf 21(11): 1202-15, November 2012.

28. Lo Re V 3rd, Volk J, Newcomb CW, Yang YX, Freeman CP, Hennessy S, Kostman JR, Tebas P, Leonard MB, Localio AR: Risk of hip fracture associated with hepatitis C virus infection and hepatitis C/HIV coinfection. Hepatology 56(5): 1688-98, November 2012.
29. Raphael BA, Dorey-Stein ZL, Lott J, Amorosa VK, Lo Re V 3rd, Kovarik C: Low prevalence of necrolytic acral erythema in patients with chronic hepatitis C virus infection. J Am Acad Dermatol 67(5): 962-8, November 2012.
30. Goldberg DS, Lewis JD, Halpern SD, Weiner M, Lo Re V 3rd: Validation of a coding algorithm to identify patients with hepatocellular carcinoma in an administrative database. Pharmacoepidemiol Drug Saf 22(1): 103-7, January 2013.
31. Lo Re V 3rd, Teal V, Localio AR, Amorosa VK, Kaplan DE, Gross R: Adherence to hepatitis C virus therapy in HIV/hepatitis C-coinfected patients. AIDS Behav 17(1): 94-103, January 2013.
32. Amorosa VK, Aibana O, Shire NJ, Dorey-Stein Z, Ferrara T, Gilmore J, Kostman JR, Lo Re V 3rd: Willingness to undergo a repeat liver biopsy among HIV/hepatitis C virus-coinfected and hepatitis C virus-monoinfected patients. J Clin Gastroenterol 47(5): 457-60, June 2013.
33. Lo Re V 3rd, Haynes K, Goldberg D, Forde KA, Carbonari DM, Leidl KBF, Hennessy S, Reddy KR, Pawloski PA, Daniel GW, Cheetham TC, Iyer A, Coughlin KO, Toh S, Boudreau DM, Cooper WO, Selvam N, Selvan MS, VanWormer JJ, Avigan MI, Houstoun M, Zornberg GL, Racoosin JA, Shoaibi A: Validity of diagnostic codes to identify cases of severe acute liver injury in the U.S. Food and Drug Administration's Mini-Sentinel Distributed Database. Pharmacoepidemiol Drug Saf 22(8): 861-72, Aug 2013.
34. Edelman EJ, Gordon KS, Lo Re V 3rd, Skanderson M, Fiellin DA, Justice AC: Acetaminophen receipt among HIV-infected patients with advanced hepatic fibrosis. Pharmacoepidemiol Drug Saf 22(12): 1352-6, December 2013.
35. Anderson JP, Tchetgen Tchetgen EJ, Lo Re V 3rd, Tate JP, Williams PL, Seage GR 3rd, Horsburgh CR, Lim JK, Goetz MB, Rimland D, Rodriguez-Barradas MC, Butt AA, Klein MB, Justice AC: Antiretroviral therapy reduces the rate of hepatic decompensation among HIV- and hepatitis C virus-coinfected veterans. Clin Infect Dis 58(5): 719-27, March 2014.
36. Keller SC, Momplaisir F, Lo Re V 3rd, Newcomb C, Liu Qing, Ratcliffe SJ, Long JA: Colorectal cancer incidence and screening in US Medicaid patients with and

without HIV infection. AIDS Care 26(6): 716-22, March 2014.

37. Lo Re V 3rd, Kallan MJ, Tate J, AR Localio, Lim JK, Goetz MB, Klein MB, Rimland D, Rodriguez-Barradas MC, Butt AA, Gibert CL, Brown ST, Park L, Dubrow R, Reddy KR, Kostman JR, Strom BL, Justice AC: Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: A cohort study. Ann Intern Med 160(6): 369-79, March 2014.
38. Hafkin JS, Osborn MK, Localio AR, Amorosa VK, Kostman JR, Stern JJ, De La Torre P, Mounzer K, Frank I, Gross R, Chang KM, Lo Re V 3rd: Incidence and risk factors for incomplete hepatitis B virus DNA suppression in HIV/hepatitis B-coinfected patients receiving tenofovir-based antiretroviral therapy. J Viral Hepat 21(4): 288-96, Apr 2014.
39. Lim JK, Tate J, Fultz SL, Goulet JL, Rimland D, Conigliaro J, Bryant KJ, Gordon AJ, Gibert C, Fiellin DA, Justice AC, Lo Re V 3rd: Relationship between alcohol use categories and noninvasive markers of advanced hepatic fibrosis in HIV-infected, chronic hepatitis C virus-infected, and uninfected patients. Clin Infect Dis 58(10): 1449-58, May 2014.
40. Byrne DD, Newcomb CW, Carbonari DM, Nezamzadeh MS, Leidl KBF, Herlim M, Yang YX, Hennessy S, Kostman JR, Leonard MB, Localio AR, Lo Re V 3rd: Risk of hip fracture associated with untreated and treated chronic hepatitis B virus infection. J Hepatol 61(2): 210-8, June 2014.
41. Byrne DD, Newcomb CW, Carbonari DM, Nezamzadeh MS, Leidl KBF, Herlim M, Yang YX, Hennessy S, Kostman JR, Leonard MB, Localio AR, Lo Re V 3rd: Prevalence of diagnosed chronic hepatitis B infection among US Medicaid enrollees, 2000-2007. Ann Epidemiol 24(6): 418-23, June 2014.
42. Yehia BR, Schranz AJ, Umscheid CA, Lo Re V 3rd: The treatment cascade for chronic hepatitis C virus infection in the United States: A systematic review and meta-analysis. PLoS One 9(7): e101554, July 2014.
43. Lo Re V 3rd, Wang L, Devine S, Baser O, Olufade T: Hepatic decompensation in patients with HIV/hepatitis B virus (HBV)/hepatitis C virus (HCV) triple infection versus HIV/HCV coinfection and the effect of anti-HBV nucleos(t)ide therapy. Clin Infect Dis 59(7): 1027-31, October 2014.
44. Armah KA, Lim JK, Lo Re V 3rd, Baker J, Tracy R, Butt AA, Agan B, Rimland D, Justice AC, Freiberg MS: HIV infection, antiretroviral therapy initiation and longitudinal changes in biomarkers of organ function. Curr HIV Res 12(1): 50-59, December 2014.
45. Gowda C, Compher C, Amorosa VK, Lo Re V 3rd: Association between chronic

hepatitis C virus infection and low muscle mass in U.S. adults. J Viral Hepat 21(12): 938-43, December 2014.

46. Cai B, Hennessy S, Lo Re V 3rd, Small DS: Epidemiologic research using probabilistic outcome definitions. Pharmacoepidemiol Drug Saf 24(1): 19-26, January 2015.
47. Butt AA, Yan P, Lo Re V 3rd, Rimland D, Goetz MB, Leaf D, Freiberg MS, Klein MB, Justice AC, Sherman KE, ERCHIVES (Electronically Retrieved Cohort of HCV Infected Veterans) Study Team: Liver fibrosis progression in hepatitis C virus infection after seroconversion. JAMA Intern Med 175(2): 178-85, February 2015.
48. Kitahata MM, Drozd DR, Crane HM, Van Rompaey SE, Althoff KN, Gange SJ, Klein MB, Lucas GM, Abraham AG, Lo Re V 3rd, McReynolds J, Lober WB, Mendes A, Modur SP, Jing Y, Morton EJ, Griffith MA, Freeman AM, Moore RD: Ascertainment and verification of end stage renal and liver disease outcomes in the North America AIDS Cohort Collaboration on Research and Design. AIDS Res Treat 2015: 923194, February 2015.
49. Ogdie AR, Pang WG, Forde KA, Bhangle SD, Mulugeta L, Chang KM, Kaplan DE, Amorosa VK, Kostman JR, Reddy KR, Schumacher HR, Lo Re V 3rd: Prevalence and risk factors for patient-reported joint pain among patients with HIV/hepatitis C coinfection, hepatitis C monoinfection, and HIV monoinfection. BMC Musculoskelet Disord 16(19): 93, April 2015.
50. Saine ME, Carbonari DM, Newcomb CW, Nezamzadeh MS, Haynes K, Roy JA, Cardillo S, Hennessy S, Holick CN, Esposito DB, Gallagher AM, Bhullar H, Strom BL, Lo Re V 3rd: Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs. BMC Pharmacol Toxicol 16(2): 8, April 2015.
51. Goldberg DS, Forde KA, Haynes K, Lewis JD, Carbonari DM, Leidl KBF, Nezamzadeh MS, Reddy KR, Roy J, Sha D, Marks AR, De Boer J, Strom BL, Corley DA, Lo Re V 3rd: Population-representative incidence of drug-induced acute liver failure based on an analysis of an integrated healthcare system. Gastroenterology 148(7): 1353-61, June 2015.
52. Lo Re V 3rd, Carbonari DM, Forde KA, Goldberg DS, Lewis JD, Haynes K, Leidl KBF, Reddy KR, Roy J, Sha D, Marks AR, Schneider JL, Strom BL, Corley DA: Validity of diagnostic codes and laboratory tests of liver dysfunction to identify acute liver failure events. Pharmacoepidemiol Drug Saf 24(7): 676-83, July 2015.
53. Lo Re V 3rd, Kallan MJ, Tate J, Lim JK, Goetz MB, Klein MB, Rimland D, Rodriguez-Barradas MC, Butt AA, Gibert CL, Brown ST, Park L, Dubrow R, Reddy KR, Kostman JR, Justice AC, Localio AR: Predicting risk of end-stage

liver disease in antiretroviral-treated HIV/hepatitis C virus-coinfected patients. Open Forum Infect Dis 2(3): ofv109, July 2015.

54. Hernandez-Trujillo H, Orange JS, Roy JA, Wang Y, Newcomb CN, Liu Q, Hennessy S, Lo Re V 3rd: Validity of primary immunodeficiency disease diagnoses in United States Medicaid data. J Clin Immunol 35(6): 566-572, August 2015.
55. Butt AA, Yan P, Shaikh OS, Freiberg MS, Lo Re V 3rd, Justice AC, Sherman KE: Virologic response and hematologic toxicity of boceprevir- and telaprevir-containing regimens in actual clinical settings. J Viral Hepat 22(9): 691-700, September 2015.
56. Carbonari DM, Saine ME, Newcomb CW, Blak B, Roy JA, Haynes K, Wood J, Gallagher AM, Bhullar H, Cardillo S, Hennessy S, Strom BL, Lo Re V 3rd: Use of demographic and pharmacy data to identify patients included within both the Clinical Practice Research Datalink (CPRD) and The Health Improvement Network (THIN). Pharmacoepidemiol Drug Saf 24(9): 999-1003, September 2015.
57. Lo Re V 3rd, Lynn K, Stumm E, Long J, Nezamzadeh MS, Baker JF, Kapalko A, Mounzer K, Tebas P, Kostman JR, Leonard MB: Structural bone deficits in HIV/HCV-coinfected, HCV-monoinfected, and HIV-monoinfected women. J Infect Dis 212(6): 924-33, September 2015.
58. Gowda C, McKittrick N, Kim D, Kappes R, Lo Re V 3rd, Tebas P: Obesity is not associated with impaired immune response to influenza vaccination in HIV-infected persons. AIDS Res Treat 2015: Article ID 653840, October 2015.
59. Byrne DD, Newcomb CW, Carbonari DM, Nezamzadeh MS, Leidl KBF, Herlim M, Yang YX, Hennessy S, Kostman JR, Leonard MB, Localio AR, Lo Re V 3rd: Increased risk of hip fracture associated with dually-treated HIV/hepatitis B virus coinfection. J Viral Hepat 22(11): 936-47, November 2015.
60. Lo Re V 3rd, Haynes K, Forde KA, Goldberg DS, Lewis JD, Carbonari DM, Leidl KBF, Reddy KR, Nezamzadeh MS, Roy J, Sha D, Marks AR, De Boer J, Schneider JL, Strom BL, Corley DA: Risk of acute liver failure in patients with drug-induced liver injury: Evaluation of Hy's Law and a new prognostic model. Clin Gastroenterol Hepatol 13(13): 2360-8, December 2015.
61. Lo Re V 3rd, Carbonari DM, Lewis JD, Forde KA, Goldberg DS, Reddy KR, Haynes K, Roy JA, Sha D, Marks AR, Schneider JL, Strom BL, Corley DA: Oral azole antifungal medications and risk of acute liver injury, overall and by chronic liver disease status. Am J Med 129(3): 283-91, e5, March 2016.
62. Rogal SS, Yan P, Rimland D, Lo Re V 3rd, Al-Rowais H, Fried L, Butt AA: Incidence and progression of chronic kidney disease after hepatitis C

seroconversion: Results from ERCHIVES. Dig Dis Sci 61(3): 930-6, March 2016.

63. Bhattacharya D, Tseng CH, Tate JP, Lo Re V 3rd, Gibert C, Butt A, Brown S, Lim JK, Rodriguez-Barradas MC, Rimland D, Kaufman E, Justice AC, Goetz MB: Isolated hepatitis B core antibody is associated with advanced hepatic fibrosis in HIV/HCV infection. J Acquir Immune Defic Syndr 72(1): e14-17, May 2016.
64. Lo Re V 3rd, Gowda C, Urick PN, Halladay JT, Binkley A, Carbonari DM, Battista K, Peleckis C, Gilmore J, Roy JA, Doshi JA, Reese PP, Reddy KR, Kostman JR: Disparities in absolute denial of modern hepatitis C therapy by type of insurance. Clin Gastroenterol Hepatol 14(7): 1035-4, July 2016.
65. Tetrault JM, Tate JP, Edelman EJ, Gordon AJ, Lo Re V 3rd, Lim JK, Rimland D, Goulet J, Crystal S, Gaither JR, Gibert CL, Rodriguez-Barradas M, Fiellin LE, Bryant K, Justice AC, Fiellin DA: Hepatic safety of buprenorphine in HIV-infected and uninfected patients with opioid use disorder: The role of HCV infection. J Subst Abuse Treat 68: 62-7, September 2016.
66. Gowda C, Brown TT, Compher C, Forde KA, Kostman JR, Shaw P, Tien PC, Lo Re V 3rd: Prevalence and predictors of low muscle mass in HIV/viral hepatitis coinfection. AIDS 30(16): 2519-28, October 2016.
67. Klein MB, Althoff KN, Jing Y, Lau B, Kitahata M, Lo Re V 3rd, Kirk GD, Hull M, Kim HN, Sebastiani G, Moodie E, Silverberg MJ, Sterling TR, Thorne JE, Cescon A, Napravnik S, Eron J, Gill MJ, Justice AC, Peters MG, Goedert J, Mayor A, Thio CL, Cachay ER, Moore R, North American AIDS Cohort Collaboration on Research and Design of IeDEA; North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA.: Risk of end-stage liver disease in HIV-viral hepatitis co-infected persons in North America from the early to modern antiretroviral therapy eras. Clin Infect Dis 63(9): 1160-7, November 2016.
68. Gowda C, Carbonari DM, Forde KA, Goldberg DS, Lewis JD, Reddy KR, Roy JA, Carey M, Liu J, Marks AR, Schneider JL, Corley DA, Lo Re V 3rd: Risk of acute liver injury with antiretroviral therapy by viral hepatitis status. Open Forum Infect Dis 4(2): ofx012, January 2017.
69. Lum KJ, Newcomb CW, Roy JA, Carbonari DM, Saine ME, Cardillo S, Bhullar H, Gallagher AM, Lo Re V 3rd: Evaluation of methods to estimate missing days' supply within pharmacy data of the Clinical Practice Research Datalink (CPRD) and The Health Improvement Network (THIN). Eur J Clin Pharmacol 73(1): 115-123, January 2017.
70. Gowda C, Sheikh U, Maier A, Chang KM, Kaplan DE, Lo Re V 3rd, Amorosa VK: Identifying barriers and potential strategies to improve hepatocellular carcinoma surveillance for HBV-infected Veterans. Fed Pract 34 (Suppl 4): S20-29, June

2017.

71. Butt AA, Ren Y, Lo Re V 3rd, Taddei TH, Kaplan DE: Comparing Child-Pugh, MELD and FIB-4 to predict clinical outcomes in HCV-infected persons: Results from ERCHIVES. Clin Infect Dis 65(1): 64-72, July 2017.
72. Taylor BS, So-Armah, Tate JP, Marconi VC, Koethe J, Bedimo R, Butt AA, Gibert CL, Goetz MB, Rodriguez-Barradas MC, Womack JA, Gerschenson M, Lo Re V 3rd, Rimland D, Yin MT, Leaf D, Tracy RP, Justice AC, Freiberg MS: HIV and obesity comorbidity increases interleukin 6 but not soluble CD14 or D-dimer. J Acquir Immune Defic Syndr 75(5): 500-508, July 2017.
73. Lo Re V 3rd, Carbonari DM, Saine ME, Newcomb CW, Roy JA, Liu Q, Wu Q, Cardillo S, Haynes K, Kimmel SE, Reese PP, Margolis DJ, Apter AJ, Reddy KR, Hennessy S, Bhullar H, Gallagher AM, Esposito DB, Strom BL: Post-authorization safety study of the DPP-4 inhibitor saxagliptin: A large-scale multi-national family of cohort studies of five outcomes. BMJ Open Diabetes Res Care 5: e000400, August 2017.
74. Coppock D, Zambo D, Moyo D, Tanthuma G, Chapman J, Lo Re V 3rd, Graziani A, Lowenthal E, Hanrahan N, Littman-Quinn R, Kovarik C, Albarracin D, Holmes JH, Gross R: Development and usability of a smartphone application for tracking antiretroviral medication refill data for human immunodeficiency virus. Methods Inf Med 56(5): 351-359, September 2017.
75. Byrne DD, Tate JP, Forde KA, Kostman JA, Lim JK, Goetz MB, Rimland D, Rodriguez-Barradas MC, Butt AA, Gibert CL, Brown ST, Bedimo R, Freiberg MS, Justice AC, Kostman JR, Roy JA, Lo Re V 3rd: Risk of acute liver injury after statin initiation by human immunodeficiency virus and chronic hepatitis C virus infection status. Clin Infect Dis 65(9): 1542-50, October 2017.
76. Lo Re V 3rd, Zeldow B, Kallan MJ, Tate JP, Carbonari DM, Kostman JR, Gross R, Justice AC, Roy JA: Risk of liver decompensation with cumulative use of mitochondrial toxic nucleoside analogues in HIV/hepatitis C virus coinfection. Pharmacoepidemiol Drug Saf 26(10): 1172-1181, October 2017.
77. So-Armah KA, Lim JK, Lo Re V 3rd, Tate JP, Chang CH, Butt AA, Gibert CL, Rimland D, Marconi V, Goetz MB, Rodriguez-Barradas MC, Budoff MJ, Tindle HA, Samet JH, Justice AC, Freiberg MS: FIB-4 stage of liver fibrosis predicts incident heart failure among HIV-infected and uninfected patients. Hepatology 66(4): 1286-1295, October 2017.
78. Justice AC, Gordon KS, Skanderson M, Edelman EJ, Akgün K, Gibert C, Lo Re V 3rd, Rimland D, Womack J, Wyatt CM, Tate JP: Nonantiretroviral polypharmacy and adverse health outcomes among HIV-infected and uninfected individuals. AIDS 32(6): 739-49, March 2018.

79. Kushner T, Shaw PA, Kalra A, Magaldi LN, Monpara P, Bedi G, Krok K, Centkowski S, Dalldorf K, D'Souza J, Haleboua-De Marzio D, Goldberg DS, Levine LD, Srinivas SK, Lewis JD, Forde KA, Lo Re V 3rd: Incidence, determinants, and outcomes of pregnancy-associated hepatitis B flares: A regional hospital-based cohort study. Liver Int 38(5): 813-20, May 2018.
80. Gowda C, Lott S, Grigorian M, Carbonari DM, Saine ME, Trooskin S, Roy JA, Kostman JR, Urick P, Lo Re V 3rd: Absolute insurer denial of direct-acting antiviral therapy for hepatitis C: A national specialty pharmacy cohort study. Open Forum Infect Dis 5(6): ofy076, June 2018.
81. Li DK, Ren Y, Fierer DS, Rutledge S, Saikh OS, Lo Re V 3rd, Simon T, Abou-Samra A, Chung RT, Butt AA: The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: an ERCHIVES study. Hepatology 67(6): 2243-53, June 2018.
82. Roy J, Lum KJ, Dworkin JD, Lo Re V 3rd, Daniels MJ: Bayesian nonparametric generative models for causal inference with missing at random covariates. Biometrics 74: 1193-1202, July 2018.
83. Saine ME, Gizaw M, Carbonari DM, Newcomb CW, Roy JA, Cardillo S, Esposito DB, Bhullar H, Gallagher AM, Strom BL, Lo Re V 3rd: Validity of diagnostic codes to identify hospitalizations for infections among patients treated with oral anti-diabetic drugs. Pharmacoepidemiol Drug Saf 27(10): 1147-1150, October 2018.
84. Rentsch CT, Cartwright EJ, Gandhi NR, Brown ST, Rodriguez-Barradas MC, Goetz MB, Marconi VC, Gibert C, Lo Re V 3rd, Fiellin DA, Justice AC, Tate JP: Provider verification of electronic health record receipt and non-receipt of direct-acting antivirals for the treatment of hepatitis C virus infection. Ann Epidemiol 28(11): 808-811, November 2018.
85. Althoff KN, Gebo KA, Moore RD, Boyd CM, Justice AC, Wong C, Lucas GM, Klein MB, Kitahata MM, Crane H, Silverberg MJ, Gill MJ, Mathews WC, Dubrow R, Horberg MA, Rabkin CS, Klein DB, Lo Re V 3rd, Sterling TR, Desir FA, Lichtenstein K, Willig J, Rachlis AR, Kirk GD, Anastos K, Pallella Jr. F, Thorne JE, Eron J, Jacobson LP, Napravnik S, Achenbach C, Mayor AM, Patel P, Buchacz K, Jing Y, Gange SJ: Contributions of traditional and HIV-related risk factors on non-AIDS-defining cancer, myocardial infarction, and end-stage liver and renal diseases in adults with HIV in the USA and Canada: A collaboration of cohort studies. Lancet HIV 6(2): e93-e104, February 2019.
86. Butt AA, Yan P, Lo Re V 3rd, Shaikh OS, Ross DB: Trends in treatment uptake and provider specialty for HCV infection in the VA healthcare system: Results from ERCHIVES. Clin Infect Dis 68(5): 857-859, February 2019.

87. Torgersen J, So-Armah K, Freiberg MS, Goetz MB, Budoff MJ, Lim JK, Taddei T, Butt AA, Rodriguez-Barradas MC, Justice AC, Kostman JR, Lo Re V 3rd: Comparison of the prevalence, severity, and risk factors for hepatic steatosis in HIV-infected and uninfected people. BMC Gastroenterol 19(1): 52, April 2019.
88. Sawinski D, Forde KA, Lo Re V 3rd, Goldberg DS, Cohen JB, Locke JE, Bloom RD, Brensinger C, Weldon J, Shults J, Reese PP: Mortality and kidney transplantation outcomes among hepatitis C virus-seropositive maintenance dialysis patients: A retrospective cohort study. Am J Kidney Dis 73(6): 815-826, June 2019.
89. Lo Re V 3rd, Newcomb CW, Carbonari DC, Roy JA, Althoff KN, Kitahata MM, Reddy KR, Lim, JK, Silverberg MJ, Mayor AM, Horberg MA, Cachay ER, Kirk GD, Hull M, Gill J, Sterling TR, Kostman JR, Peters MG, Moore RD, Klein MB, Kim HN: Determinants of liver complications among HIV/hepatitis B virus-coinfected patients. J Acquir Immune Defic Syndr 82(1): 71-80, September 2019.
90. Zeldow B, Lo Re V 3rd, Roy J: A semiparametric modeling approach using Bayesian Additive Regression Trees with an application to evaluate heterogeneous treatment effects. Ann Appl Stat 13(3): 1989-2010, September 2019.
91. Saine ME, Carbonari DM, Newcomb CW, Gallagher AM, Blak BT, Roy JA, Wood J, Cardillo S, Hennessy S, Strom BL, Lo Re V 3rd: Concordance of hospitalizations between Clinical Practice Research Datalink and linked Hospital Episode Statistics among patients treated with oral anti-diabetic therapies. Pharmacoepidemiol Drug Saf 28(10): 1328-35, October 2019.
92. Torgersen J, Taddei TH, Park LS, Carbonari DM, Kallan MJ, Richard KA, Zhang X, Jhala D, Bräu N, Homer R, D'Addeo K, Mehta R, Skanderson M, Kidwai-Khan F, Justice AC, Lo Re V 3rd: Differences in pathology, staging, and treatment between HIV+ and uninfected patients with microscopically confirmed hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev 29(1): 71-78, January 2020.
93. Saine ME, Moore TM, Szymczak JE, Bamford LP, Barg FK, Mitra N, Schnittker J, Holmes JH, Lo Re V 3rd: Validation of a modified Berger HIV stigma scale for use among patients with hepatitis C virus (HCV) infection. PLoS One 15(2): e0228471, February 2020.
94. So-Armah KA, Lim JK, Lo Re V 3rd, Tate JP, Chang CH, Butt AA, Gibert CL, Rimland D, Marconi V, Goetz MB, Ramachandran V, Brittain E, Long M, Nguyen KL, Rodriguez-Barradas MC, Budoff MJ, Tindle HA, Samet JH, Justice AC, Freiberg MS: FIB-4 stage of liver fibrosis is associated with incident heart failure with preserved, but not reduced, ejection fraction among people with and without HIV or hepatitis C. Prog Cardiovasc Dis 63(2): 184-91, March 2020.

95. Baker JF, Leonard CE, Lo Re V 3rd, Weisman MH, George MD, Kay J: Biosimilar uptake in the academic and Veterans Health Administration settings: Influence of institutional incentives. Arthritis Rheumatol 72(7): 1067-71, July 2020.
96. Do A, Esserman DA, Krishnan S, Lim JK, Taddei TH, Hauser RG 3rd, Tate JP, Lo Re V 3rd, Justice AC: Excess weight gain after cure of hepatitis C infection with direct-acting antivirals. J Gen Intern Med 35(7): 2025-2034, July 2020.
97. Rhodes JM, Lo Re V 3rd, Mato AR, Chong EA, Barrientos JC, Gerson JN, Barta SK, Landsburg DJ, Nasta SD, Svoboda J, Loren AW, Schuster SJ: Ibrutinib-associated arthralgias/myalgias in patients with chronic lymphocytic leukemia: Incidence and impact on clinical outcomes. Clin Lymphoma Myeloma Leuk 20(7): 438-44, July 2020.
98. Torgersen J, Kallan MJ, Carbonari DM, Park LS, Mehta RL, D'Addeo K, Tate JP, Lim JK, Goetz MB, Rodriguez-Barradas MC, Gibert CL, Bräu N, Brown ST, Roy JA, Taddei TH, Justice AC, Lo Re V 3rd: HIV RNA, CD4+ percentage, and risk of hepatocellular carcinoma by cirrhosis status. J Natl Cancer Inst 112(7): 747-755, July 2020.
99. Butt AA, Yan P, Shaikh OS, Lo Re V 3rd, Abou-Samra AB, Sherman KE: Treatment of HCV reduces viral hepatitis-associated liver-related mortality in patients: An ERCHIVES study. J Hepatol 73(2): 277-284, August 2020.
100. Rentsch CT, Kidwai-Khan F, Tate JP, Park LS, King JT Jr, Skanderson M, Hauser RG, Schultze A, Jarvis CI, Holoniy M, Lo Re V 3rd, Akgün KM, Crother K, Taddei TH, Freiberg MS, Justice AC: Patterns of COVID-19 testing and mortality by race and ethnicity among United States veterans: A nationwide cohort study. PLoS Med 17(9): e1003379, September 2020.
101. Saine ME, Szymczak JE, Moore TM, Bamford LP, Barg FK, Schnittker J, Holmes JH, Mitra N, Lo Re V 3rd: Determinants of stigma among patients with hepatitis C virus (HCV) infection. J Viral Hepat 27(11): 1179-89, November 2020.
102. Wang W, Lo Re V 3rd, Guo Y, Xiao H, Brown J, Park H: Impact of hepatitis C virus treatment on the risk of non-hepatic cancers among hepatitis C virus infected patients in the U.S. Aliment Pharmacol Ther 52(10): 1592-1602, November 2020.
103. van Boemmel-Wegmann S, Lo Re V 3rd, Park H: Treatment uptake and cost burden of hepatitis C (HCV) therapies among HCV patients with a particular focus on HIV coinfection. Dig Dis Sci 65(11): 3159-74, November 2020.
104. Gelfand JM, Armstrong AW, Bell S, Anesi G, Blauvelt A, Calabrese, C, Dommasch E, Feldman SR, Gladman D, Kircik L, Lebwohl M, Lo Re V 3rd, Martin G,

Merola J, Scher J, Schwartzman S, Treat J, Van Voorhees A, Ellebrecht C, Fenner J, Ocon A, Syed M, Weinstein EJ, Smith J, Gondo G, Heydon S, Koons S, Ritchlin CR: National Psoriasis Foundation COVID-19 Task Force Guidance for the Management of Psoriatic Disease During the Pandemic: Version 1. J Am Acad Dermatol 83(6): 1704-16, December 2020.

105. Torgersen J, Kallan MJ, Carbonari DM, Park LS, Mehta RL, D'Addeo K, Tate JP, Lim JK, Goetz MB, Rodriguez-Barradas MC, Bräu N, Brown ST, Taddei TH, Justice AC, Lo Re V 3rd: Accuracy of FIB-4 for cirrhosis in people living with HIV and hepatocellular carcinoma. J Acquir Immune Defic Syndr 85(5): 530-4, December 2020.
106. Marquez LK, Chaillon A, Soe KP, Johnson D, Zosso JM, Incerti A, Loarec A, Nguyen A, Walker JG, Mafirakureva N, Lo Re V 3rd, Wynn A, McIntosh C, Kiene SM, Brodine S, Garfein RS, Vickerman P, Martin NK: Cost and cost-effectiveness of a real-world HCV treatment program among HIV-infected individuals in Myanmar. BMJ Glob Health 6(2): e004181, February 2021.
107. Bykov K, Li H, Kim S, Vine SM, Lo Re V 3rd, Gagne JJ: Drug-drug interaction surveillance study: comparing self-controlled designs in five empirical examples in real-world data. Clin Pharmacol Ther 109(5): 1353-60, May 2021.
108. Gelfand JM, Armstrong AW, Bell S, Anesi G, Blauvelt A, Calabrese C, Dommasch E, Feldman SR, Gladman D, Kircik L, Lebwohl M, Lo Re V 3rd, Martin G, Merola J, Scher J, Schwartzman S, Treat J, Van Voorhees A, Ellebrecht C, Fenner J, Ocon A, Syed M, Weinstein EJ, Smith J, Gondo G, Heydon S, Koons S, Ritchlin CR: National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 2 - Advances in Psoriatic Disease Management, COVID-19 Vaccines, and COVID-19 Treatments. J Am Acad Dermatol 84(5): 1254-68, May 2021.
109. Luo C, Jiang Y, Du J, Tong J, Huang J, Lo Re V 3rd, Ellenberg SS, Poland GA, Tao C, Chen Y: Prediction of post-vaccination Guillain-Barré syndrome using data from a passive surveillance system. Pharmacoepidemiol Drug Saf 30(5): 602-9, May 2021.
110. Lavery CLM, Olave M, Leonard CE, Lo Re V 3rd, Shea JA, Kay J, Baker JF: Knowledge of biosimilars and perceptions of the naming conventions for biosimilar products in clinical practice in the United States. Drugs & Therapy Perspectives 37: 338-46, June 2021.
111. Duncan MS, Alcorn CW, Freiberg MS, So-Armah K, Patterson OV, DuVall SL, Crothers KA, Lo Re V 3rd, Butt AA, Lim JK, Kim JW, Tindle HA, Justice AC, Brittain EL: Association between HIV and incident pulmonary hypertension in US Veterans: a retrospective cohort study. Lancet Healthy Longev 2(7): e417-e425, July 2021.

112. Jiang X, Song HJ, Wang W, Henry L, Childs-Kean LM, Lo Re V 3rd, Park H: The use of all-oral direct-acting antivirals in hepatitis C virus-infected patients with substance use disorders. J Manag Care Spec Pharm 27(7): 873-81, July 2021.
113. Lo Re V 3rd, Carbonari DM, Jacob J, Short WR, Leonard CE, Lyons JG, Kennedy A, Damon J, Haug N, Zhou EH, Graham DJ, McMahon-Walraven CN, Parlett LE, Nair V, Selvan M, Zhou Y, Pacobelli G, Maro JC, Nguyen MD: Validity of ICD-10-CM diagnoses to identify hospitalizations for serious infections among patients treated with biologic therapies. Pharmacoepidemiol Drug Saf 30(7): 899-909, July 2021.
114. Park H, Jiang X, Song HJ, Lo Re V 3rd, Childs-Kean LM, Lo-Ciganic WH, Cook RL, Nelson DR: The impact of direct-acting antiviral therapy on end-stage liver disease among individuals with chronic hepatitis C and substance use disorders Hepatology 74(2): 566-581, August 2021.
115. Kim HN, Newcomb CW, Carbonari DM, Roy JA, Torgersen J, Althoff KN, Kitahata MM, Reddy KR, Lim JK, Silverberg MJ, Mayor AM, Horberg MA, Cachay ER, Kirk GD, Sun J, Hull M, Gill MJ, Sterling TR, Kostman JR, Peters MG, Moore RD, Klein MB, Lo Re V 3rd: Risk of hepatocellular carcinoma with hepatitis B viremia among HIV/HBV-coinfected persons in North America. Hepatology 74(3): 1190-1202, September 2021.
116. Weinstein EJ, Stephens-Shields A, Loabile B, Yuh T, Silibovsky R, Nelson CL, O'Donnell JA, Hsieh E, Hanberg JS, Akgün KN, Tate JP, Lo Re V 3rd: Development and validation of case-finding algorithms to identify prosthetic joint infections after total knee arthroplasty in Veterans Health Administration data. Pharmacoepidemiol Drug Saf 30(9): 1184-91, September 2021.
117. Justice AC, Gordon KS, Romero J, Edelman EJ, Garcia BJ, Jones P, Khoo S, Lo Re V 3rd, Rentsch CT, Tate JP, Tseng A, Womack J, Jacobson D: Polypharmacy-associated risk of hospitalisation among people ageing with and without HIV: An observational study. Lancet Healthy Longev Page: e639-650, October 2021.
118. Saine ME, Szymczak JE, Moore TM, Bamford LP, Barg FK, Forde KA, Schnittker J, Holmes JH, Mitra N, Lo Re V 3rd: The impact of disease-related knowledge on perceptions of stigma among patients with hepatitis C virus (HCV) infection. PLoS One 16(10): e0258143, October 2021.
119. Torgersen J, Newcomb CW, Carbonari DM, Rentsch CT, Park LS, Mezocho A, Mehta RL, Buchwalder L, Tate JP, Bräu N, Bhattacharya D, Lim JK, Taddei TH, Justice AC, Lo Re V 3rd: PI-based HCV DAAs are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensation. J Hepatol 75(6): 1312-1322, December 2021.

120. Young J, Lo Re V 3rd, Kim HN, Sterling TR, Althoff KN, Gebo KA, Gill MJ, Horberg MA, Mayor AM, Moore RD, Silverberg MJ, Klein MB: Do contemporary antiretrovirals increase the risk of end-stage liver disease? Signals from patients starting therapy in the North American AIDS Cohort Collaboration on Research and Design. Pharmacoepidemiol Drug Saf 31: 214-24, February 2022.
121. Kim HN, Nance RM, Lo Re V 3rd, Silverberg MJ, Franco R, Sterling TR, Cachay ER, Horberg MA, Althoff KN, Justice AC, Moore RD, Klein M, Crane HM, Delaney JA, Kitahata MM: Development and validation of a model for prediction of end-stage liver disease in people with HIV. J Acquir Immune Defic Syndr 89(4): 396-404, April 2022.
122. Vakili S, Paneru B, Guerrier CM, Baumrin E, Forrestel A, Lynn K, Frank I, Lo Re V 3rd, Collman RG, Hill DA: Altered adipose tissue macrophage populations in people with HIV on integrase inhibitor-containing ART. AIDS Page: In Press. May 2022.
123. Lo Re V 3rd, Dutcher SK, Connolly JG, Perez-Vilar S, Carbonari DM, DeFor TA, Djibo DA, Harrington LB, Hou L, Hennessy S, Hubbard RA, Kempner ME, Kuntz JL, McMahonill-Walraven CN, Mosley J, Pawloski PA, Petrone AB, Pishko AM, Rogers Driscoll M, Steiner CA, Zhou Y, Cocoros NM: Association of COVID-19 versus influenza with risk of arterial and venous thrombotic events among hospitalized patients. JAMA 328(7): 637-51, August 2022.
124. Ferrante ND, Newcomb CW, Forde KA, Leonard CE, Torgersen J, Linas BP, Rowan SE, Wyles DL, Kostman JR, Trooskin SB, Lo Re V 3rd: The hepatitis C care cascade during the direct-acting antiviral era in a United States commercially-insured population. Open Forum Infect Dis 9(9): ofac445, September 2022.
125. Haque LY, Fiellin DA, Tate JP, Esserman D, Bhattacharya D, Butt AA, Crystal S, Edelman EJ, Gordon AJ, Lim JK, Tetrault JM, Williams EC, Bryant K, Cartwright EJ, Rentsch CT, Justice AC, Lo Re V 3rd, McGinnis KA: Association between alcohol use disorder and receipt of direct-acting antiviral hepatitis C treatment. JAMA Netw Open Page: In Press. October 2022.
126. Hawks L, Wang EA, Butt AA, Crystal S, McInnes DK, Lo Re V 3rd, Cartwright EJ, Puglisi LB, Haque LYK, Lim JK, Justice AC, McGinnis KA: The Veterans Health Administration approach to universal hepatitis C treatment: Reach to individuals with prior incarceration. Am J Public Health Page: In Press. October 2022.
127. Titanji BK, Lee, M, Wang Z, Chen J, Hui Q, Lo Re V 3rd, So-Armah K, Justice AC, Xu K, Freiberg MS, Gwinn M, Marconi VC, Sun YV: Epigenome-wide

association study of biomarkers of liver function identifies albumin-associated DNA methylation sites among male Veterans with HIV. Front Genet Page: In Press. October 2022.

Research Publications, peer-reviewed reviews:

1. Lo Re V 3rd, Brennan PJ, Wadlin J, Weaver R, Nachamkin I: Infected branchial cleft cyst due to *Bordetella bronchiseptica* in an immunocompetent patient. J Clin Microbiol 39(11): 4210-2, November 2001.
2. Lo Re V 3rd, Gluckman SJ: Eosinophilic meningitis due to *Angiostrongylus cantonensis* in a returned traveler: case report and review of the literature. Clin Infect Dis 33(9): e112-5, November 2001.
3. Lo Re V 3rd, Bellini LM: William of Occam and Occam's razor. Ann Intern Med 136(8): 634-5, April 2002.
4. Lo Re V 3rd, Gluckman SJ: Eosinophilic meningitis due to *Gnathostoma spinigerum*. J Infect 45(2): 117-20, August 2002.
5. Lo Re V 3rd, Gluckman SJ: Eosinophilic meningitis. Am J Med 114(3): 217-23, February 2003.
6. Lo Re V 3rd, Fishman NO, Nachamkin I: Recurrent catheter-related *Rhodotorula rubra* infection. Clin Microbiol Infect 9(8): 897-900, August 2003.
7. Lo Re V 3rd, Gluckman SJ: Prevention of malaria in travelers. Am Fam Phys 68(3): 509-14, August 2003.
8. Lo Re V 3rd, Fox KR, Ferrari VA, Scott CH, Kossev PM, Kostman JR: Hypereosinophilia associated with cardiac rhabdomyosarcoma. Am J Hematol 74(1): 64-7, September 2003.
9. Lo Re V 3rd, Gluckman SJ: Fever in the returned traveler. Am Fam Phys 68(7): 1343-50, October 2003.
10. Lo Re V 3rd, Occi JL, MacGregor RR: Identifying the vector of Lyme disease. Am Fam Phys 69(8): 1935-7, Apr 2004.
11. Lo Re V 3rd, Gluckman SJ: Travel immunizations. Am Fam Phys 70(1): 89-99, July 2004.
12. Lo Re V 3rd, Kostman JR: Anemia during treatment of hepatitis C in HIV-infected patients. AIDS Reader 14(10): 555-7, 562, 565-71, October 2004.
13. Lo Re V 3rd, Kostman JR: Management of chronic hepatitis C. Postgrad Med J 81(956): 376-82, June 2005.

14. Samaha F, Ky B, Lo Re V 3rd: Type III hyperlipoproteinemia unmasked by HIV antiretroviral therapy. Am J Med 118(6): 691-2, June 2005.
15. Lo Re V 3rd, Bellini LM: William Pepper Jr, MD (1843-1898): portrait of a nineteenth-century medical educator. J Med Biogr 14(3): 169-77, August 2006.
16. Lo Re V 3rd, Strom BL: The role of academia and the research community in assisting the Food and Drug Administration to ensure U.S. drug safety. Pharmacoepidemiol Drug Saf 16(7): 818-25, July 2007.
17. Dorey-Stein Z, Amorosa VK, Kostman JR, Lo Re V 3rd, Shannon RP: Severe weight gain, lipodystrophy, dyslipidemia, and obstructive sleep apnea in a human immunodeficiency virus-infected patient following highly active antiretroviral therapy. J Cardiometab Syndr 3: 111-4, March 2008.
18. Lo Re V 3rd, Kostman JR, Amorosa VK: Management complexities of HIV/hepatitis C virus coinfection in the twenty-first century. Clin Liver Dis 12(3): 587-609, August 2008.
19. Bedimo R, Maalouf NM, Lo Re V 3rd: Hepatitis C virus coinfection as a risk factor for osteoporosis and fracture. Curr Opin HIV AIDS 11(3): 285-93, May 2016.
20. Taddei TH, Lo Re V 3rd, Justice AC: HIV, aging, and viral coinfections: Taking the long view. Curr HIV/AIDS Rep 13(5): 269-78, September 2016.
21. Midgard H, Weir A, Palmateer N, Lo Re V 3rd, Pineda JA, Macías J, Dalgard O: HCV epidemiology in high-risk groups and the risk of reinfection. J Hepatol 65: S33-45, October 2016.
22. Gowda C, Lo Re V 3rd: Strategies for the elimination of hepatitis C virus infection as a public health threat in the United States. Curr Hepatol Rep 17: 111-20, June 2018.
23. Ghany MG, Marks KM, Morgan TR, Wyles DL, Aronsohn AI, Bhattacharya D, Broder T, Falade-Nwulia OO, Feld JJ, Gordon SC, Heller T, Jhaveri RR, Jonas MM, Kiser JJ, Linas BP, Lo Re V 3rd, Peters MG, Reddy KR, Reynolds A, Scott JD, Searson G, Spradling P, Terrault NA, Trooskin SB, Verna EC, Wong JB, Woolley AE, Workowski KA: Hepatitis C Guidance 2019 Update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Hepatology 71(2): 686-721, February 2020.
24. Ferrante ND, Lo Re V 3rd: Epidemiology, natural history, and treatment of hepatitis delta virus infection in HIV/hepatitis B virus coinfection. Curr HIV/AIDS Rep 17(4): 405-14, August 2020.

25. Lo Re V 3rd, Klungel OH, Chan KA, Panozzo CA, Zhou W, Winterstein AG: Global covid-19 vaccine rollout and safety surveillance-how to keep pace. BMJ 373: n1416, June 2021.
26. Cocoros NM, Fuller CC, Adimadhyam S, Ball R, Brown JS, Dal Pan GJ, Kluberg SA, Lo Re V 3rd, Maro JC, Nguyen M, Orr R, Paraoan D, Perlin J, Poland RE, Rogers Driscoll M, Sands K, Toh S, Yih WK, Platt R: A COVID-19-ready public health surveillance system: The Food and Drug Administration's Sentinel System. Pharmacoepidemiol Drug Saf 30(7): 727-37, July 2021.
27. Girman CJ, Ritchey ME, Lo Re V 3rd: Real-world data: Assessing electronic health records and medical claims data to support regulatory decision-making for drug and biological products. Pharmacoepidemiol Drug Saf 31(7): 717-20, July 2022.
28. Weinstein EJ, Ritchey ME, Lo Re V 3rd: Core concepts in pharmacoepidemiology: Validation of health outcomes of interest within real-world healthcare databases. Pharmacoepidemiol Drug Saf Page: In Press. September 2022.

Contributions to peer-reviewed research publications, participation cited but not by authorship:

1. Leake JA, Mosley DG, England B, Graham JV, Plikaytis BD, Ampel NM, Perkins BA, Hajjeh RA: Risk factors for acute symptomatic coccidioidomycosis among elderly persons in Arizona, 1996-1997. J Infect Dis 181: 1435-40, April 2000.

Research Publications, non-peer reviewed:

[none]

Abstracts (Last 3 years):

1. Krishnan S, Akgun KM, Tate JP, Bryant K, Crystal S, Lo Re V 3rd, Rentsch C, Crothers K, Gordon K, Oursler KA, Justice AC: Neurocognitively-acting potentially inappropriate medications, alcohol, and delirium among patients with and without HIV. 23rd International Workshop on HIV and Hepatitis Observational Databases, Athens, Greece March 2019 Notes: Poster presentation Abstract 245.
2. Marquez LK, Chaillon A, Soe KP, Johnson D, Zosso JM, Incerti A, Loarec A, Nguyen A, Walker J, Mafirakureva N, Lo Re V 3rd, Wynn A, Vickerman P, Martin NK: Cost-effectiveness of HCV treatment among HIV-positive individuals in Myanmar. Conference on Retroviruses and Opportunistic Infections 2019, Seattle, WA March 2019 Notes: Poster presentation Abstract 590.
3. Torgersen J, Kallan MJ, Carbonari DM, Roy JA, Park LS, Taddei T, Mehta R, D'Addeo K, Lim JK, Goetz MB, Tate JP, Bräu N, Justice AC, Lo Re V 3rd: HIV viremia and low CD4+ count increase HCC risk in those without advanced liver fibrosis. Conference on Retroviruses and Opportunistic Infections 2019, Seattle, WA March 2019 Notes: Oral Abstract 90.

4. Zola C, Duncan MS, So-Armah K, Crothers K, Butt AA, Gibert CL, Lim JK, Lo Re V 3rd, Tindle HA, Freiberg MS, Brittain EL: HIV/HCV-specific markers and echocardiographic pulmonary artery systolic pressure. Conference on Retroviruses and Opportunistic Infections 2019, Seattle, WA March 2019 Notes: Poster presentation Abstract 659.
5. Binkley A, Torgersen J, Gilmore J, O'Neal J, Saine ME, Russell R, Short W, Lo Re V 3rd: Elimination of hepatitis C virus in HIV-coinfected patients in a viral hepatitis center: A multi-disciplinary approach. 13th American Conference for the Treatment of HIV, Miami, FL April 2019 Notes: Poster presentation Abstract 6.
6. Wang W, Lo Re V 3rd, Guo Y, Xiao H, Brown J, Park HS: The clinical and economic impact of HCV treatment on non-hepatic cancers among HCV-infected patients. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2019, New Orleans, LA May 2019 Notes: Oral Abstract 92677.
7. Wang W, Lo Re V 3rd, Guo Y, Xiao H, Brown J, Park HS: The increased risks of non-hepatic cancers among hepatitis C virus (HCV)-infected patients: A population-based cohort study in the US. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2019, New Orleans, LA May 2019 Notes: Oral Abstract 92652.
8. Saine ME, Szymczak JE, Lo Re V 3rd: A conceptual model to evaluate disease-related stigma and access to healthcare among patients with hepatitis C virus infection. 35th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Philadelphia, PA August 2019 Notes: Poster presentation Abstract 1009.
9. Rhodes J, Mato A, Hubbard R, Chong E, Winchell N, Kennard K, Nasta S, Landsburg D, Gerson J, Bartta S, Svoboda J, Loren A, Lo Re V 3rd, Schuster S: Characteristics and outcomes of ibrutinib-associated musculoskeletal toxicities in CLL patients. International Workshop on CLL, Edinburgh, Scotland September 2019 Notes: Oral Abstract 1990.
10. Butt AA, Yan P, Aslam S, Lo Re V 3rd, Shaikh O: Reduction in liver-related mortality among HCV-Infected persons is driven by attainment of SVR independent of the regimen used: Results from the ERCHIVES cohort. ID Week 2019, Washington DC October 2019 Notes: Oral Abstract 676567.
11. Sun J, Althoff KN, Kim HN, Kitahata MM, Achenbach CJ, D'Souza G, Klein MB, Lau B, Lim JK, Lo Re V 3rd, Marcus JL, Mayor AM, Silverberg MJ, Kirk GD: Hepatocellular carcinoma risk among persons with HIV in North America, 1996-2015. Conference on Retroviruses and Opportunistic Infections 2020, Boston, MA March 2020 Notes: Oral Abstract 3009.

12. Torgersen J, Kallan MJ, Carbonari DM, Park LS, Mehta R, D'Addeo K, Tate JP, Lim JK, Goetz MB, Rodriguez-Barradas MC, Bräu N, Brown ST, Taddei TH, Justice AC, Lo Re V 3rd: Accuracy of FIB-4 for cirrhosis in HIV+ patients with hepatocellular carcinoma. Conference on Retroviruses and Opportunistic Infections 2020, Boston, MA March 2020 Notes: Poster presentation Abstract 2428.
13. Bykov K, Li H, Kim S, Lo Re V 3rd, Gagne JJ: Drug-drug interaction surveillance study: Comparing self-controlled designs in five empirical examples in real-world data 36th International Conference on Pharmacoepidemiology & Therapeutic Risk Management - All Access Virtual Meeting 2020 September 2020 Notes: Poster presentation Abstract PO-2406.
14. Saine ME, Szymczak JE, Barg FK, Lo Re V 3rd: Stigma as a barrier to the hepatitis C virus continuum Of care in the era of direct-acting antiviral therapies. 36th International Conference on Pharmacoepidemiology & Therapeutic Risk Management - All Access Virtual Meeting 2020 September 2020 Notes: Poster presentation Abstract PO-4442.
15. Saine ME, Szymczak JE, Moore TM, Bamford LP, Barg FK, Schnittker J, Holmes JH, Mitra N, Lo Re V 3rd: Determinants of stigma among patients with hepatitis C virus (HCV) infection. 36th International Conference on Pharmacoepidemiology & Therapeutic Risk Management - All Access Virtual Meeting 2020 September 2020 Notes: Poster presentation Abstract MYPO-05.
16. Torgersen J, Newcomb CW, Carbonari DM, Rentsch C, Park L, Mehta R, D'Addeo K, Taddei T, Justice AC, Lo Re V 3rd: Risk of acute liver injury with protease inhibitor-based antiviral therapy for hepatitis C. 36th International Conference on Pharmacoepidemiology & Therapeutic Risk Management - All Access Virtual Meeting 2020 September 2020 Notes: Poster presentation Abstract PO-4654.
17. Saine ME, Szymczak JE, Forde KA, Moore TM, Bamford LP, Barg FK, Schnittker J, Holmes JH, Mitra N, Lo Re V 3rd: The impact of hepatitis C-related knowledge on perceptions of stigma among infected individuals. ID Week 2020 Virtual Meeting October 2020 Notes: Poster presentation Abstract 1072.
18. Lavery C, Olave M, Leonard C, Lo Re V 3rd, Shea J, Kay J, Baker J: Knowledge of biosimilars and perceptions of biosimilar naming conventions in clinical practice. American College of Rheumatology Convergence 2020 All Virtual November 2020 Notes: Poster presentation Abstract 902639.
19. Mezocho A, Torgersen J, Newcomb CW, Carbonari DM, Hennessy S, Park LS, Mehta RL, Tate JP, Taddei TH, Justice AC, Lo Re V 3rd: Risk of severe acute liver injury among initiators of potentially hepatotoxic drugs. Liver Meeting Digital Experience 2020 November 2020 Notes: Oral Abstract 119.

20. Park LS, Zhang X, Nalbantoglu I, Kidwai-Khan F, Mehta RL, Carbonari DC, Torgersen J, Lo Re V 3rd, Justice AC, Taddei TH: A histological resource to examine HIV and aging mechanisms for hepatocellular carcinoma. Liver Meeting Digital Experience 2020 November 2020 Notes: Poster presentation Abstract 1030.
21. Cartwright EJ, Pierret C, Rentsch CT, Minassian C, Tate JP, Fiellin DA, Justice AC, Lo Re V 3rd: Relationship between alcohol use and sustained virologic response to HCV DAA therapy. Virtual Conference on Retroviruses and Opportunistic Infections 2021 March 2021 Notes: Science Spotlight Abstract 2099.
22. Kim HN, Nance RM, Crane H, Whitney BM, Althoff KN, Moore R, Silverberg MJ, Mayor A, Cachay ER, Hull M, Lo Re V 3rd, Klein MB, Delaney JA, Kitahata MM: Prediction model for end-stage liver disease among people with HIV in the NA-ACCORD. Virtual Conference on Retroviruses and Opportunistic Infections 2021 March 2021 Notes: Science Spotlight Abstract 1472.
23. Kim HN, Newcomb CW, Carbonari DM, Cachay ER, Gill MJ, Hull M, Kostman JR, Kim JK, Silverberg MJ, Horberg MA, Mayor A, Kitahata MM, Klein MB, Lo Re V 3rd: Hepatocellular carcinoma and HBV viremia in HIV/HBV-coinfected persons in NA-ACCORD. Virtual Conference on Retroviruses and Opportunistic Infections 2021 March 2021 Notes: Oral Abstract 1486.
24. Klein MB, Young J, Althoff KN, Cachay ER, Franco R, Gill MJ, Horberg MA, Hull M, Kim HN, Lo Re V 3rd, Moore R, Price J, Sebastiani G, Silverberg MJ: Are modern antiretrovirals hepatotoxic? Signals in patients starting ART in NA-ACCORD. Virtual Conference on Retroviruses and Opportunistic Infections 2021 March 2021 Notes: Science Spotlight Abstract 1220.
25. Hawks L, Wang EA, Butt A, Crystal S, McInnes K, Lo Re V 3rd, Lim J, Cartwright E, Puglisi L, Haque L, McGinnis KA: The HCV treatment cascade by incarceration status in patients with and without HIV. Society for General Internal Medicine Annual Meeting 2021 April 2021 Notes: Poster presentation Abstract PSSA11-0021.
26. Weinstein EJ, Stephens-Shields A, Loabile B, Yuh T, Silibovsky R, Nelson CL, O'Donnell JA, Hsieh E, Hanberg JS, Akgün KN, Tate JP, Lo Re V 3rd: Development and validation of case-finding algorithms to identify prosthetic joint infections after total knee arthroplasty 37th International Conference on Pharmacoepidemiology & Therapeutic Risk Management - All Access Virtual Meeting 2021 August 2021 Notes: Oral Abstract L3B4.
27. Gasior J, Russell R, Lo Re V 3rd, Norris AH, Bennett S, Aitcheson N, Ferrante ND, Evans C, Patel M, Mehta S, Torgersen J: Automated hepatitis C screening and linkage to care among hospitalized patients born between 1945-1965. Virtual ID Week 2021 September 2021 Notes: Poster presentation Abstract 1071509.

28. Akgün K, Krishnan S, Tate JP, Bryant K, Crystal S, Pisani M, Lo Re V 3rd, Rentsch CT, Crothers K, Gordon K, Oursler KA, Justice AC: Potentially inappropriate medications and delirium in people with and without HIV in a nested case-control study. 24th International Workshop on HIV and Hepatitis Observational Databases, Seville, Spain March 2022 Notes: Poster presentation Abstract 160.
29. Ferrante ND, Newcomb CW, Forde KA, Leonard CE, Torgersen J, Linas BP, Rowan SE, Wyles DL, Kostman J, Trooskin SB, Lo Re V 3rd: The hepatitis C care cascade during the direct-acting antiviral era within a nationally representative United States health claims database. Digestive Disease Week 2022, San Diego, CA May 2022 Notes: Oral Abstract 3689090.
30. Haque LY, Fiellin DA, Tate JP, Esserman D, Bhattacharya D, Butt AA, Crystal S, Edelman, EJ, Gordon AJ, Lim JK, Tetrault JM, Williams EC, Bryant K, Cartwright EJ, Rentsch CT, Justice AC, Lo Re V 3rd, McGinnis KA: Alcohol use disorder is associated with lower receipt of direct-acting antiviral hepatitis C treatment: A national cohort study. College on Problems of Drug Dependence Annual Meeting, Minneapolis, MN June 2022 Notes: Poster presentation Abstract S7.
31. Cocoros NM, Dutcher SK, Connolly JG, Perez-Vilar S, Carbonari DM, DeFor TA, Djibo DA, Harrington LB, Hou L, Hennessy S, Hubbard RA, Kempner ME, Kuntz JL, McMahon-Walraven CN, Mosley J, Pawloski PA, Petrone AB, Pishko AM, Rogers Driscoll M, Steiner CA, Zhou Y, Lo Re V 3rd: Arterial and venous thrombotic events in patients with COVID-19 compared to influenza. 38th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Copenhagen, Denmark August 2022 Notes: Oral Abstract 158.
32. Ferrante ND, Kallan MJ, Sukkestad S, Kodani M, Kitahata MM, Cachay E, Bhattacharya D, Heath S, Napravnik S, Moore R, Yendewa G, Mayer KH, Hayden T, Kamili S, Martin J, Kim N, Lo Re V 3rd: Prevalence of hepatitis delta virus (HDV) infection among HIV/HBV-coinfected adults in care in the United States. The Liver Meeting 2022, Washington DC November 2022 Notes: Poster presentation Abstract 33911.
33. Haque LY, Chew M, Taddei TH, Justice AC, Lo Re V 3rd, Tate JP: Validity of an algorithm to identify hepatic decompensation using a national electronic health record. The Liver Meeting 2022, Washington DC November 2022 Notes: Poster presentation Abstract 32594.

Editorials, Reviews, Chapters, including participation in committee reports (print or other media):

1. Lo Re V 3rd, Barton T, Feiner S: A pain in the back [Letter] N Engl J Med 344(6): 456, February 2001.

2. Lo Re V 3rd, Fishman NO: Recognition and management of anthrax [Letter] N Engl J Med 346(12): 943-5, March 2002.
3. Lo Re V 3rd, Kostman JR: Predictors of severe liver fibrosis in HIV-infected patients with chronic hepatitis C [Letter] Clin Infect Dis 38(12): 1789-90, June 2004.
4. Lo Re V 3rd: Economic analysis of hepatitis B screening and treatment. Clin Infect Dis 52(11): 1307-1309, June 2011.
5. Lo Re V 3rd, Reddy KR: Hepatobiliary complications of HIV. Handbook of Liver Disease, 3rd Edition. Friedman LS, Keeffe EB (eds.). Elsevier, 2012.
6. Lo Re V 3rd, Tate JP, Lim JK, Fiellin DA, Justice AC: Reply to Marcellin et al. Clin Infect Dis 59(8): 1192-3, October 2014.
7. Justice AC, Freiberg MS, Lo Re V 3rd: Should everyone aging with HIV take a statin? Lancet HIV 2(2): e36-e37, February 2015.
8. Lo Re V 3rd, Schuster M: Evaluating hepatitis B virus reactivation during solid tumor chemotherapy: Evidence to guide pretreatment hepatitis B screening and prophylaxis. Ann Intern Med 164(1): 64-65, January 2016.
9. National Academies of Sciences, Engineering, and Medicine. 2016: Eliminating the public health problem of hepatitis B and C in the United States: Phase one report. Washington, DC: The National Academies Press April 2016 Notes: doi: 10.17226/23407.
10. Lo Re V 3rd, Forde KA, Lewis JD, Goldberg DS, Carbonari DM, Roy JA, Reddy KR, Sha D, Strom BL, Corley DA: Reply: Is Sensitivity the Key Measure to Predict Acute Liver Failure in Drug-Induced Liver Injury Patients? Clin Gastroenterol Hepatol 14(6): 918-919, June 2016 Notes: Is sensitivity the key measure to predict acute liver failure in drug-induced liver injury patients? [Letter]
11. Lo Re V 3rd: Extrahepatic complications of hepatitis C virus infection in HIV and the impact of successful antiviral treatment. Clin Infect Dis 64(4): 498-500, February 2017.
12. Lo Re V 3rd, Carbonari DM, Lewis JD, Roy JA, Corley DA.: Reply: Effects of Treatment with Azoles Are Overstated. Am J Med 130(8): e369, August 2017.
13. Lo Re V 3rd: Is moderate alcohol consumption safe for HIV/hepatitis C virus-coinfected women? Clin Infect Dis 65(12): 2057-59, November 2017.
14. Lo Re V 3rd, Reddy KR: Hepatobiliary complications of HIV. Handbook of Liver Disease, 4th Edition. Friedman LS, Martin P (eds.). Elsevier, 2017.

15. Lo Re V 3rd: Validation of health outcomes of interest in healthcare databases. Pragmatic Randomized Clinical Trials. Using Primary Data Collection and Electronic Health Records. Girman CJ, Ritchey ME (eds.). Academic Press, 2021.
16. Torgersen J, Taddei TH, Lo Re V 3rd: Reply to: Is it safe to treat chronic hepatitis C patients with decompensated cirrhosis with PI-based DAA? J Hepatol 77(1): 258-9, July 2022.
17. Li X, Lo Re V 3rd, Toh S: Profiling real-world data sources for pharmacoepidemiologicresearch: A call for papers. Pharmacoepidemiol Drug Saf 31(9): 929-31, September 2022.

Books:

1. Infectious Diseases Hot Topics. Lo Re V 3rd (eds.). Hanley & Belfus, 2004.

Alternative Media:

1. Lo Re V 3rd, Gluckman SJ: Eosinophilic meningitis. MD Consult Infectious Disease. MD Consult, April 2002.
2. Lo Re V 3rd: Principal agents of bioterrorism: recognition and management. Psychiatric Times 22(14): 40, December 2005.
3. Lo Re V 3rd: Addressing anticipated adherence problems prior to hepatitis C virus treatment. Hepatitis C Online (<http://www.hepatitisc.uw.edu>). August 2013.
4. Gowda C, Lo Re V 3rd: What's behind fatigue, elevated liver enzymes? The Philadelphia Inquirer June 2015 Notes: June 28, 2015.
5. Lo Re V 3rd: Access to Direct-Acting Antiviral Therapy for Chronic HCV: Any Progress? AGA Perspectives (<http://agaperspectives.gastro.org/>) November 2016.

Patents:

[none]